WO2024128305A1 - 2-アザビシクロ[3.1.1]ヘプタン化合物 - Google Patents

2-アザビシクロ[3.1.1]ヘプタン化合物 Download PDF

Info

Publication number
WO2024128305A1
WO2024128305A1 PCT/JP2023/044987 JP2023044987W WO2024128305A1 WO 2024128305 A1 WO2024128305 A1 WO 2024128305A1 JP 2023044987 W JP2023044987 W JP 2023044987W WO 2024128305 A1 WO2024128305 A1 WO 2024128305A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
azabicyclo
methyl
biphenyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2023/044987
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
暁丈 山口
尚弘 竹本
薫 松下
順 小林
正治 乾
雅大 井上
俊介 前原
康司 安部
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Priority to AU2023395547A priority Critical patent/AU2023395547A1/en
Priority to JP2024564440A priority patent/JPWO2024128305A1/ja
Priority to KR1020257019334A priority patent/KR20250112793A/ko
Priority to EP23903586.8A priority patent/EP4635944A1/en
Priority to CN202380092851.0A priority patent/CN120603816A/zh
Publication of WO2024128305A1 publication Critical patent/WO2024128305A1/ja
Priority to MX2025006722A priority patent/MX2025006722A/es
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • the present invention relates to a compound having a specific chemical structure or a pharma- ceutical acceptable salt thereof that can be used as an agonist of the orexin type 2 receptor.
  • Orexin is a neuropeptide that is specifically produced in certain neurons localized in the lateral hypothalamus, and is an endogenous ligand for the orexin receptor, a G protein-coupled receptor that is found primarily in the brain.
  • Non-Patent Document 1 Orexin-deficient mice show symptoms very similar to those of human narcolepsy (Non-Patent Document 1), and it has been reported that intracerebroventricular administration of orexin peptides reduces symptoms such as suppressing cataplexy and increasing alertness (Non-Patent Document 2). It has also been reported that orexin concentrations in the cerebrospinal fluid of narcolepsy patients are significantly reduced (Non-Patent Document 3), suggesting that narcolepsy is caused by a deficiency of orexin.
  • Non-Patent Document 4 There are two subtypes of orexin receptors: type 1 (OX1R) and type 2 (OX2R) (Non-Patent Document 4). Mutations in OX2R have been reported as a cause of hereditary narcolepsy in dogs (Non-Patent Document 5). It has also been shown that OX2R-deficient mice exhibit narcolepsy-like symptoms (Non-Patent Document 6), suggesting that OX2R is strongly involved in maintaining wakefulness. In light of this background, it has been suggested that OX2R agonists could be therapeutic drugs for diseases that present with narcolepsy and hypersomnia symptoms (Non-Patent Document 7). To date, compounds described in Patent Documents 1 to 9, for example, have been reported as OX2R agonists, but all of them are structurally different from the compound of the present invention.
  • idiosyncratic liver toxicity (IDT) caused by taking drugs is a severe toxicity that occurs in about 1 in 100,000 people, and is very difficult to predict from animal experiments (Non-Patent Document 8).
  • One of the mechanisms of onset is known to be the covalent bond between electrophilic reactive metabolites (ERMs) generated during the drug metabolism and biopolymers (Non-Patent Document 9). It is useful to reduce the risk of IDT by coexisting glutathione (GSH) as a nucleophile in an in vitro metabolic reaction system using human liver microsomes and using the formation of GSH conjugates as an indicator.
  • GSH glutathione
  • the objective of the present invention is to provide a novel compound that acts as an agonist on the orexin type 2 receptor and can be used to treat diseases associated with the orexin type 2 receptor, particularly narcolepsy.
  • the present invention relates to the following (1) to (14).
  • R 1 represents a phenyl group or a pyridyl group which may have one or two substituents independently selected from the following Group A, a phenyl group substituted with five deuterium atoms, a 2,2-difluoro-1,3-benzodioxolyl group, or a 5-membered heteroaryl group containing in the ring one or two atoms independently selected from the group consisting of a nitrogen atom and a sulfur atom,
  • the heteroaryl group may have one or two substituents independently selected from the following Group B:
  • R2 represents a C1 - C6 alkyl group which may have 1 to 5 substituents independently selected from Group C below, a C3 - C6 cycloalkyl group which may have 1 or 2 substituents independently selected from Group D below, a 4- or 5-membered saturated heterocyclic group containing in the ring one atom independently selected from the group consisting of nitrogen atoms and oxygen atoms, a 5-
  • R 1 represents a phenyl group or a pyridyl group which may have one or
  • R 2 represents a C 1 -C 6 alkyl group which may have 1 to 5 substituents independently selected from the group consisting of a hydroxyl group, a fluorine atom, and a deuterium atom, a cyclopropyl group which may be substituted by 1 or 2 fluorine atoms, or an isoxazolyl group; The compound according to (1) or (2) or a pharma- ceutically acceptable salt thereof.
  • R3 represents a fluorine atom
  • R4 represents a hydrogen atom or a fluorine atom
  • Z represents CH or a nitrogen atom
  • R5 represents a methyl group, an ethyl group, a monofluoromethyl group, or a cyclopropyl group
  • R 6 represents a hydrogen atom or a fluorine atom
  • R 1 represents the following formula (II):
  • R 11 and R 12 each independently represent a hydrogen atom, a fluorine atom, or a chlorine atom.
  • R 2 is any one of R 2a to R 2e below,
  • R 3 , R 4 and R 6 each independently represent a hydrogen atom or a fluorine atom;
  • R5 represents a methyl group or an ethyl group;
  • Z represents CH or a nitrogen atom;
  • a pharmaceutical composition comprising the compound according to any one of (1) to (8) or a pharma- ceutically acceptable salt thereof.
  • An orexin type 2 receptor agonist comprising the compound according to any one of (1) to (8) or a pharma- ceutically acceptable salt thereof.
  • a prophylactic or therapeutic agent for narcolepsy comprising the compound according to any one of (1) to (8) or a pharma- ceutically acceptable salt thereof.
  • a method for preventing or treating narcolepsy which comprises administering an effective amount of the compound according to any one of (1) to (8) or a pharma- ceutically acceptable salt thereof.
  • the compound of the present invention or a pharma- ceutical acceptable salt thereof acts as an excellent orexin type 2 receptor agonist. Furthermore, the specific compound of the present invention or a pharma-ceutical acceptable salt thereof can provide the effect of excellent metabolic stability and/or low IDT risk.
  • halogen atom is, for example, a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom.
  • a "C 1 -C 6 alkyl group” is a straight-chain or branched-chain alkyl group having 1 to 6 carbon atoms, such as a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a s-butyl group, a t-butyl group, a pentyl group, an isopentyl group, a 2-methylbutyl group, a neopentyl group, a 1-ethylpropyl group, a hexyl group, an isohexyl group, or a 4-methylpentyl group.
  • the "C 1 -C 6 alkoxy group” refers to an alkoxy group formed from the above C 1 -C 6 alkyl group, such as a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a butoxy group, an isobutoxy group, a s-butoxy group, a t-butoxy group, a pentoxy group, a isopentoxy group, a 2-methylbutoxy group, a neopentoxy group, a 1-ethylpropoxy group, a hexoxy group, an isohexoxy group, or a 4-methylpentoxy group.
  • the " C3 - C6 cycloalkyl group” is, for example, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, or a cyclohexyl group.
  • the "C 1 -C 6 alkylamino group” refers to a group in which one of the above-mentioned C 1 -C 6 alkyl groups is bonded to an amino group, and examples thereof include a methylamino group, an ethylamino group, a propylamino group, an isopropylamino group, a butylamino group, an isobutylamino group, a s-butylamino group, a t-butylamino group, a pentylamino group, an isopentylamino group, a 2-methylbutylamino group, a neopentylamino group, a 1-ethylpropylamino group, a hexylamino group, an isohexylamino group, and a 4-methylpentylamino group.
  • the "di-C 1 -C 6 alkylamino group” refers to a group in which two identical or different C 1 -C 6 alkyl groups as described above are bonded to an amino group, and examples thereof include a dimethylamino group, a methylethylamino group, and a diethylamino group.
  • C1- C6 alkyl group optionally substituted with 1 to 3 halogen atoms means the above C1 - C6 alkyl group and a group in which the above C1 - C6 alkyl group is substituted with the same or different halogen atoms.
  • Examples of the above C1 - C6 alkyl group substituted with the same or different halogen atoms include a fluoromethyl group, a difluoromethyl group, a trifluoromethyl group, a chloromethyl group, a dichloromethyl group, and a trichloromethyl group.
  • C 1 -C 6 alkyl group optionally substituted with 1 to 3 hydroxyl groups means the above C 1 -C 6 alkyl group and a group in which the above C 1 -C 6 alkyl group is substituted with a hydroxyl group.
  • Examples of the above C 1 -C 6 alkyl group substituted with a hydroxyl group include a hydroxymethyl group, a 1-hydroxyethyl group, a 2-hydroxyethyl group, a 1-hydroxy-1-methylethyl group, and a 2-hydroxy-1-methylethyl group.
  • C1- C6 alkoxy group optionally substituted with 1 to 3 halogen atoms refers to the above C1 - C6 alkoxy group and the above C1 - C6 alkoxy group substituted with the same or different halogen atoms.
  • Examples of the above C1 - C6 alkoxy group substituted with the same or different halogen atoms include a fluoromethoxy group, a difluoromethoxy group, a trifluoromethoxy group, a chloromethoxy group, a dichloromethoxy group, and a trichloromethoxy group.
  • saturated heterocycle means a saturated ring that contains a heteroatom within the ring.
  • heteroaryl group refers to a substituent derived from an aromatic ring that contains a heteroatom.
  • a “biaryl group” refers to a substituent having a structure in which two aromatic rings are linked by a single bond, and one or both of the aromatic rings constituting the biaryl group may be a heteroaryl group.
  • the "five-membered heteroaryl group containing one or two atoms independently selected from the group consisting of nitrogen atoms and sulfur atoms in the ring” is, for example, a pyrrolyl group, a thienyl group, a pyrazolyl group, an imidazolyl group, a thiazolyl group, or an isothiazolyl group.
  • the "5-membered heteroaryl group containing one or two atoms in the ring independently selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom” is, for example, a furyl group, a pyrrolyl group, a thienyl group, a pyrazolyl group, an imidazolyl group, an isoxazolyl group, or an oxazolyl group.
  • a 4- or 5-membered saturated heterocyclic group containing one atom selected from the group consisting of a nitrogen atom and an oxygen atom in the ring refers to, for example, an azetidinyl group, an oxetanyl group, a pyrrolidinyl group, or a tetrahydrofuranyl group.
  • R 1 is preferably a phenyl group, a 3,5-difluorophenyl group, or a 3-chlorophenyl group, and more preferably a phenyl group.
  • R 2 is preferably any one of R 2a to R 2e below, and more preferably R 2d or R 2e .
  • a preferred combination of R 3 , R 4 and Z is any one of R 3a to R 3c below, and more preferably R 3a or R 3c .
  • *1 is bonded to the phenyl group and *2 is bonded to the methylene group.
  • R5 is preferably a methyl group or an ethyl group, and more preferably a methyl group.
  • R6 is preferably a hydrogen atom or a fluorine atom.
  • a suitable combination of substituents in general formula (I) is that R1 is a phenyl group, R2 is R2d or R2e , the combination of R3 , R4 and Z is R3a or R3c , R5 is a methyl group, and R6 is a hydrogen atom or a fluorine atom.
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and Z in formula (III) are the same as those in formula (I) of this specification.
  • the compound of the present invention represented by general formula (I) can be converted into a pharma- ceutically acceptable salt if desired.
  • a pharma-ceutically acceptable salt refers to a salt that can be used as a medicine when administered to the body of an animal (including a human).
  • the compound of the present invention represented by general formula (I) has an acidic or basic group, it can be converted into a salt by reacting it with a base or an acid.
  • Salts based on acidic groups include, for example, alkali metal salts such as sodium salts, potassium salts, and lithium salts; alkaline earth metal salts such as magnesium salts and calcium salts; organic base salts such as N-methylmorpholine salts, triethylamine salts, tributylamine salts, diisopropylethylamine salts, dicyclohexylamine salts, N-methylpiperidine salts, pyridine salts, 4-pyrrolidinopyridine salts, and picoline salts; and amino acid salts such as glycine salts, lysine salts, arginine salts, ornithine salts, glutamate salts, and aspartate salts.
  • alkali metal salts such as sodium salts, potassium salts, and lithium salts
  • alkaline earth metal salts such as magnesium salts and calcium salts
  • organic base salts such as N-methylmorpholine salts, triethylamine salt
  • Sals based on basic groups include, for example, hydrohalides such as hydrofluoride, hydrochloride, hydrobromide, and hydroiodide; inorganic acid salts such as nitrate, perchlorate, sulfate, and phosphate; lower alkanesulfonates such as methanesulfonate, trifluoromethanesulfonate, and ethanesulfonate; arylsulfonates such as benzenesulfonate and p-toluenesulfonate; organic acid salts such as acetate, malate, fumarate, succinate, citrate, ascorbate, tartrate, oxalate, and maleate; and amino acid salts such as glycine salt, lysine salt, arginine salt, ornithine salt, glutamate, and aspartate.
  • hydrohalides such as hydrofluoride, hydrochloride, hydrobromide, and hydroiod
  • the compound of the present invention represented by general formula (I) or a pharma- ceutically acceptable salt thereof may absorb moisture and become hydrated or have adsorbed water when left in the air or when recrystallized, and the present invention also includes such various hydrates, solvates and crystalline polymorphic compounds.
  • the compound represented by the general formula (I) of the present invention may exist in various isomers such as geometric isomers such as cis-isomers and trans-isomers, tautomers, rotational isomers, or optical isomers such as d-isomers and l-isomers (including enantiomers and diastereomers) depending on the type and combination of the substituents.
  • the compound of the present invention includes all of these isomers, stereoisomers, and mixtures of these isomers and stereoisomers in any ratio unless otherwise specified. Mixtures of these isomers can be separated by known resolution means.
  • the ratio of a certain diastereomer depends on the substrate, solvent and base, but is not particularly limited.
  • the ratio of a certain diastereomer (which may be a racemate):stereoisomers other than the certain diastereomer may be 1:1 or more, or it may be a single diastereomer.
  • single diastereomer refers to a mixture of isomers of the compound according to the present invention, in which the ratio of a specific diastereomer (which may be a racemate): a stereoisomer other than the specific diastereomer is 20:5 (20/5) or more, 20:3 (20/3) or more, or 20:1 (20/1) or more.
  • the excess of the enantiomers is not particularly limited, and may be, for example, 0% ee or more (including racemate), 20% ee or more, 40% ee or more, 60% ee or more, 80% ee or more, 85% ee or more, or 90% ee or more.
  • a "single enantiomer” may mean a mixture of enantiomers according to the present invention in which the enantiomeric excess is, for example, 92% ee or more, 94% ee or more, 96% ee or more, or 99% ee or more.
  • the compound represented by general formula (I) of the present invention or a pharma- ceutically acceptable salt thereof also includes a labeled compound, i.e., a compound in which one or more atoms of the compound are replaced with an isotope (e.g., 2H , 3H , 13C , 14C , 35S , etc.).
  • a labeled compound i.e., a compound in which one or more atoms of the compound are replaced with an isotope (e.g., 2H , 3H , 13C , 14C , 35S , etc.).
  • the relative configuration can be indicated by adding an * to the configuration indication (R* and S*) when the configuration of the first asymmetric center is R or S, or by placing the prefix (symbol) rel- (meaning relative) before the name.
  • Racemic mixtures are usually designated without the R and S symbols to indicate their absolute configuration, but may be designated by the symbols RS and SR instead of R* and S*, or by the prefix (symbol) rac- (for racemic) before the name.
  • the present invention also includes so-called prodrugs.
  • a prodrug is a compound having a group that can be converted to an amino group, a hydroxyl group, a carboxyl group, or the like of a compound by hydrolysis or under physiological conditions, and examples of groups that form such prodrugs include those described in Prog. Med., Vol. 5, pp. 2157-2161, 1985, etc.
  • the prodrugs include: (1) When an amino group is present in the compound, examples of such compounds include compounds whose amino group is acylated, alkylated or phosphorylated (for example, compounds whose amino group is eicosanoylated, alanylated, pentylaminocarbonylated, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxycarbonylated, tetrahydrofuranylated, pyrrolidylmethylated, pivaloyloxymethylated or tert-butylated), and the like.
  • compounds whose amino group is acylated, alkylated or phosphorylated
  • compounds whose amino group is eicosanoylated, alanylated, pentylaminocarbonylated, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxycarbonylated, tetrahydrofuranylated, pyr
  • the compound contains a hydroxyl group
  • Examples of such compounds include compounds in which the carboxy group is esterified or amidated (for example, compounds in which the carboxy group is ethyl esterified, phenyl esterified, carboxymethyl esterified, dimethylaminomethyl esterified, pivaloyloxymethyl esterified, ethoxycarbonyloxyethyl esterified, amidated or methylamidated).
  • the compound according to the present invention can be used as a medicine for the treatment and/or prevention of narcolepsy.
  • the compound according to the present invention can be used as a medicine for the treatment, remission, and/or prevention of idiopathic hypersomnia, sleep apnea syndrome, other hypersomnia (e.g., hypersomnia associated with neurodegenerative diseases such as Parkinson's disease and dementia with Lewy bodies, and psychiatric diseases such as major depression, schizophrenia, and bipolar disorder), circadian rhythm disorders, obesity, diabetes, and hypersomnia associated with analgesics such as morphine.
  • hypersomnia e.g., hypersomnia associated with neurodegenerative diseases such as Parkinson's disease and dementia with Lewy bodies
  • psychiatric diseases such as major depression, schizophrenia, and bipolar disorder
  • circadian rhythm disorders obesity, diabetes, and hypersomnia associated with analgesics such as morphine.
  • the compound according to the present invention can be used for the treatment and prevention of the above diseases.
  • the compound according to the present invention can be used as an orexin type 2 receptor agonist, and that orexin is considered to be involved not only in the effects on sleep and awakening, but also in the effects of feeding, emotions, cognitive functions, and the like.
  • the compound according to the present invention can be used as a medicine for the prevention of the occurrence of the above diseases in order to improve the quality of life during the day by preventing excessive daytime sleepiness and cataplexy.
  • the compound of the present invention may be used as an orexin type 2 receptor agonist not only to activate the activity of an individual with reduced orexin levels, but also to normal individuals without reduced orexin levels.
  • the compound of the present invention can be used in a manner that allows the individual to maintain a wakeful state during the active period (e.g., about 12 to 16 hours) out of 24 hours, and the drug effect wears off before sleep time, making it difficult to suppress sleep.
  • the compound according to the present invention may be used in combination with existing narcolepsy treatment drugs, such as modafinil, sodium oxybate, pitolisant, methylphenidate, antidepressants, etc.
  • existing narcolepsy treatment drugs such as modafinil, sodium oxybate, pitolisant, methylphenidate, antidepressants, etc.
  • the compound according to the present invention when used to treat drug-induced hypersomnia, it may be used in combination with the drug that causes it.
  • the pharmaceutical composition of the present invention comprises the compound of the present invention or a pharma- ceutical acceptable salt thereof, and may comprise a pharma- ceutical acceptable carrier, and can be administered as various injections such as intravenous injection, intramuscular injection, subcutaneous injection, etc., or by various methods such as oral administration or transdermal administration.
  • a pharma- ceutical acceptable carrier means a pharma- ceutical acceptable material (e.g., an excipient, a diluent, an additive, a solvent, etc.) involved in transporting the compound of the present invention or a composition containing the compound of the present invention from one organ or organ to another.
  • the preparation containing the compound of the present invention or a pharma- ceutically acceptable salt thereof as an active ingredient is prepared using additives such as carriers and excipients used in conventional preparations.
  • the administration of the compound of the present invention may be in any form, such as oral administration using tablets, pills, capsules, granules, powders, liquids, etc., or parenteral administration using injections for intra-articular, intravenous, intramuscular, etc., suppositories, eye drops, eye ointments, transdermal liquids, ointments, transdermal patches, transmucosal liquids, transmucosal patches, inhalants, etc.
  • Tablets, powders, granules, etc. are used as solid compositions for oral administration.
  • Such solid compositions consist of one or more active ingredients and at least one inactive excipient, such as lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone, and/or magnesium aluminometasilicate.
  • the solid compositions may contain inactive additives, such as lubricants such as magnesium stearate, and disintegrants, stabilizers, and dissolution aids such as sodium carboxymethyl starch, according to conventional methods.
  • Tablets or pills may be coated with a sugar coating or a film of a gastric or enteric substance, if necessary.
  • carriers When used as tablets, carriers that can be used include, for example, excipients such as lactose, sucrose, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, and silicic acid; binders such as water, ethanol, propanol, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethylcellulose, shellac, methylcellulose, potassium phosphate, and polyvinylpyrrolidone; disintegrants such as dry starch, sodium alginate, agar powder, laminaran powder, sodium bicarbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid esters, sodium lauryl sulfate, stearate monoglyceride, starch, and lactose; disintegration inhibitors such as sucrose, stearin, cocoa butter, and hydrogenated oils; absorption promoters such as quaternary ammonium salts and sodium lauryl sulfate; moisturizers such as g
  • the carrier When used as a pill, the carrier may be, for example, an excipient such as glucose, lactose, cocoa butter, starch, hardened vegetable oil, kaolin, or talc; a binder such as powdered gum arabic, powdered tragacanth, gelatin, or ethanol; or a disintegrant such as laminaran or agar.
  • an excipient such as glucose, lactose, cocoa butter, starch, hardened vegetable oil, kaolin, or talc
  • a binder such as powdered gum arabic, powdered tragacanth, gelatin, or ethanol
  • a disintegrant such as laminaran or agar.
  • liquid compositions for oral administration pharma- ceutically acceptable emulsions, solutions, suspensions, syrups, elixirs, etc. are used.
  • inert diluents such as purified water or ethanol.
  • the liquid compositions may contain auxiliary agents such as solubilizers and wetting agents, sweeteners, flavorings, aromatics, and preservatives.
  • Aqueous solvents include, for example, distilled water for injection or physiological saline.
  • Non-aqueous solvents include, for example, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethanol, or polysorbate 80.
  • Such injection compositions may further contain an isotonicity agent, a preservative, a wetting agent, an emulsifier, a dispersant, a stabilizer, or a solubilizing agent.
  • injection compositions can be sterilized, for example, by filtration through a bacteria-retaining filter, by mixing with a bactericide, or by irradiation.
  • these injection compositions can be used by preparing a sterile solid composition and dissolving or suspending it in sterile water or a sterile injection solvent before use.
  • liquids, emulsions or suspensions When used as an injection, it can be used as a liquid, emulsion or suspension. These liquids, emulsions or suspensions are preferably sterilized and isotonic with blood.
  • solvents used in the production of these liquids, emulsions or suspensions, so long as they can be used as diluents for medical use, and examples of such solvents include water, ethanol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylene sorbitan fatty acid esters, etc.
  • the formulation may contain sufficient amounts of salt, glucose or glycerin to prepare an isotonic solution, and may also contain conventional solubilizing agents, buffers, soothing agents, etc.
  • the above-mentioned preparations may contain, if necessary, coloring agents, preservatives, perfumes, flavorings, sweeteners, and the like, and may further contain other medicinal agents.
  • the amount of the compound contained in the above-mentioned preparation is not particularly limited and may be appropriately selected from a wide range, but it is usually contained in an amount of 0.5 to 70% by weight, preferably 1 to 30% by weight, of the total composition.
  • the dosage and frequency of administration of the compound of the present invention are appropriately determined in consideration of the symptoms, age, etc. of the patient (warm-blooded animal, especially human).
  • the daily dosage is usually about 0.001-100mg/kg per body weight, preferably 0.1-30mg/kg, more preferably 0.1-10mg/kg, and is administered once or in two or more divided doses.
  • the daily dosage is usually about 0.0001-10mg/kg per body weight, and is administered once or in multiple divided doses.
  • the compounds of the present invention may be administered orally once a day, for example, at the time of awakening from sleep (e.g., in the morning), at a dose such that the drug effect wears off by the time the active period for that day (e.g., about 12 to 16 hours) ends and the patient enters the next sleep period, and thus the compound does not suppress sleep.
  • the compound represented by general formula (1) or a pharma- ceutically acceptable salt thereof can be produced by applying various known production methods, taking advantage of the characteristics based on the basic structure or the type of substituents.
  • Known methods include, for example, the methods described in "ORGANIC FUNCTIONAL GROUP PREPARATIONS", 2nd Edition, ACADEMIC PRESS, INC., 1989, “Comprehensive Organic Transformations”, VCH Publishers Inc., 1989, etc.
  • Such functional groups include, for example, amino groups, hydroxyl groups, and carboxyl groups, and their protecting groups include, for example, those described in "Greene's Protective Groups in Organic Synthesis” by T.W. Greene and P.G. Wuts (4th ed., John Wiley & Sons, Inc., 2006).
  • the protecting group or the group that can be easily converted to the functional group may be appropriately selected depending on the reaction conditions of each manufacturing method for producing the compound.
  • the desired compound can be obtained by introducing the group, carrying out the reaction, and then removing the protecting group as necessary or converting it to the desired group.
  • Method A is a method for producing a compound represented by general formula (1) from a compound represented by general formula (2).
  • R 1 to R 6 and Z are the same as defined above, and R 13 represents R 2 or a precursor thereof.
  • Step A-1 includes steps A-1a, A-1b, A-1c, and A-1d as essential reactions, and may include steps A-1e and A-1f as necessary. Any of steps A-1b to A-1f may be carried out first, and a person skilled in the art can easily select the order of steps A-1b to A-1f.
  • Step A-1a A reaction for introducing a methylene biaryl group or a methylene aryl group by a substitution reaction between a ⁇ -keto ester and an alkyl bromide.
  • Step A-1b A reaction for decarboxylation of a ⁇ -keto ester.
  • Step A-1c A reaction for converting a ketone into an amine.
  • Step A-1d A reaction for sulfonylation or sulfamoylation of an amine
  • Step A-1e A reaction for converting a bromine atom on the aromatic ring of a methylenearyl group into an aryl group or a heteroaryl group
  • Step A-1f A reaction for reducing an alkene
  • Step A-1a This step involves introducing a methylenebiaryl group or a methylenearyl group into a ⁇ -ketoester using an appropriate base and an alkyl bromide in an inert solvent.
  • the solvent that can be used is not particularly limited as long as it does not inhibit the reaction and dissolves the starting materials to some extent, and may be selected from the following solvent group, for example.
  • the solvent group consists of aromatic hydrocarbons such as benzene, toluene, and xylene; halogenated hydrocarbons such as dichloromethane and chloroform; ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane, and 1,2-dimethoxyethane; alcohols such as methanol, deuterated methanol, ethanol, deuterated ethanol, and tert-butanol; esters such as ethyl acetate and propyl acetate; nitriles such as acetonitrile; amides such as formamide and N,N-dimethylformamide; sulfoxides such as dimethyl sulfoxide; organic acids such as acetic acid; water; and mixtures thereof.
  • the base used is not particularly limited as long as it is one that is normally used as a base in reactions, but preferred examples include organic bases such as triethylamine, N,N-diisopropylethylamine, N-methylmorpholine, lutidine, and pyridine; alkali metal carbonates such as sodium carbonate, potassium carbonate, and cesium carbonate; alkaline earth metal carbonates such as magnesium carbonate; alkali metal hydrogen carbonates such as potassium hydrogen carbonate; alkaline earth metal hydrogen carbonates such as calcium hydrogen carbonate; alkali metal hydroxides such as sodium hydroxide; alkaline earth metal hydroxides such as magnesium hydroxide; and alkali metal phosphates such as tripotassium phosphate.
  • organic bases such as triethylamine, N,N-diisopropylethylamine, N-methylmorpholine, lutidine, and pyridine
  • alkali metal carbonates such as sodium carbonate, potassium carbonate, and cesium carbonate
  • the reaction temperature varies depending on the starting compounds, reagents, etc., but is usually from -20°C to 120°C, preferably from 0°C to 80°C.
  • the reaction time varies depending on the starting compounds, reagents, etc., but is usually from 5 minutes to 48 hours, preferably from 10 minutes to 24 hours.
  • the target compound of the reaction can be obtained, for example, by concentrating the reaction mixture, adding an organic solvent such as ethyl acetate, washing with water, separating the organic layer containing the target compound, drying it with anhydrous sodium sulfate or the like, and then distilling off the solvent. If necessary, the resulting compound can be further purified by a conventional method such as recrystallization, reprecipitation, silica gel column chromatography, and the like.
  • Step A-1b is a step of decarboxylating a ⁇ -ketoester compound.
  • Step A-1b1 decarboxylation reaction.
  • Step A-1b2 tert-butoxycarbonylation reaction can be added as necessary.
  • Step A-1b1 This step involves decarboxylating a ⁇ -ketoester using an acid or a metal salt.
  • the solvent used may be the same as that used in the above step A-1a.
  • the acid to be used is not particularly limited as long as it is an acid that is usually used in reactions, and preferable examples include inorganic acids such as hydrochloric acid, sulfuric acid, and nitric acid.
  • the metal salt to be used is not particularly limited, but examples thereof include lithium chloride and lithium sulfate.
  • the reaction temperature varies depending on the starting compounds, reagents, etc., but is usually from 0°C to 160°C, preferably from 80°C to 140°C.
  • the reaction time varies depending on the starting compounds, reagents, etc., but is usually from 5 minutes to 96 hours, preferably from 1 hour to 48 hours. After completion of the reaction, the target compound of this reaction can be obtained, for example, through steps such as concentration, separation, and drying in the same manner as in Step A-1a above, and may be further purified by a conventional method as described above, if necessary.
  • Step A-1b2 This step is a tert-butoxycarbonylation step in the presence or absence of a suitable base.
  • the solvent used may be the same as that used in the above step A-1a.
  • the tert-butoxycarbonylating agent used is not particularly limited so long as it is used as a tert-butoxycarbonylating agent in a normal reaction, and preferred examples include di-tert-butyl dicarbonate and tert-butylphthalimide carbonate.
  • the base used may be the same as that used in the above step A-1a.
  • the reaction temperature varies depending on the starting compounds, reagents, etc., but is usually from -40°C to 100°C, preferably from 0°C to 60°C.
  • the reaction time varies depending on the starting compounds, reagents, etc., but is usually from 5 minutes to 48 hours, preferably from 1 hour to 24 hours. After completion of the reaction, the target compound of this reaction can be obtained, for example, through steps such as concentration, separation, and drying in the same manner as in Step A-1a above, and may be further purified by a conventional method, as necessary,
  • Step A-1c Step A-1c is carried out by converting a ketone to an oxime, followed by reduction to an amine.
  • Step A-1c1 condensation reaction of a ketone with hydroxylamine hydrochloride
  • Step A-1c2 reduction of the oxime to an amine
  • This step involves converting a ketone to an oxime using an appropriate base and hydroxylamine hydrochloride in an inert solvent.
  • the solvent used may be the same as that used in the above step A-1a.
  • the base used may be the same as that used in the above step A-1a.
  • the reaction temperature varies depending on the starting compounds, reagents, etc., but is usually from -20°C to 120°C, preferably from 0°C to 80°C.
  • the reaction time varies depending on the starting compounds, reagents, etc., but is usually from 5 minutes to 48 hours, preferably from 30 minutes to 24 hours.
  • the target compound of this reaction can be obtained, for example, through steps such as concentration, separation, and drying in the same manner as in the above-mentioned Step A-1a, and may be further purified by a conventional method, if necessary.
  • This step involves converting an oxime to an amine using a suitable reducing agent in an inert solvent in the presence or absence of an additive.
  • the solvent used may be the same as that used in the above step A-1a.
  • the reducing agent used is not particularly limited, but examples thereof include sodium borohydride, lithium borohydride, lithium aluminum hydride, sodium cyanoborohydride, sodium triacetoxyborohydride, zinc dust, and the like.
  • the additives used are not particularly limited as long as they are used in known methods, but preferred examples include metal oxides such as molybdenum (VI) oxide; metal salts such as nickel (II) chloride; and the like.
  • the reaction temperature varies depending on the starting compounds, reagents, etc., but is usually from -20°C to 120°C, preferably from 0°C to 80°C.
  • the reaction time varies depending on the starting compounds, reagents, etc., but is usually from 5 minutes to 96 hours, preferably from 30 minutes to 48 hours.
  • the target compound of this reaction can be obtained, for example, through steps such as concentration, separation, and drying in the same manner as in the above-mentioned Step A-1a, and may be further purified by a conventional method, if necessary.
  • optically active compounds can be obtained.
  • Step A-1d This step involves sulfonylation or sulfamoylation of an amine using a suitable base and a sulfonyl chloride or a sulfamoyl chloride in an inert solvent in the presence or absence of an additive.
  • the solvent used may be the same as that used in the above step A-1a.
  • the base used may be the same as that used in the above step A-1a.
  • the additives used are not particularly limited as long as they are used in known methods, but preferred examples include N,N-dimethylaminopyridine.
  • the reaction temperature varies depending on the starting compounds, reagents, etc., but is usually from -20°C to 120°C, preferably from 0°C to 80°C.
  • the target compound of this reaction can be obtained, for example, through steps such as concentration, separation, and drying in the same manner as in the above-mentioned Step A-1a, and may be further purified by a conventional method, if necessary.
  • a conventional method if necessary.
  • This step is a step of converting the bromine atom on the aryl ring or heteroaryl ring introduced in step A-1a into an aryl group or heteroaryl group.
  • a method using a boronic acid or an ester thereof in the presence of a suitable base and a suitable metal catalyst (step A-1e1), or a method of converting the bromine atom into a boronic acid ester using a boron compound in the presence of a suitable base and a suitable metal catalyst, and then using an aryl halide or heteroaryl halide in the presence of a suitable base and a suitable metal catalyst (step A-1e2) will be described, but the present invention is not limited thereto.
  • Step A-1e1 is a step of converting a bromine atom on an aryl or heteroaryl ring to an aryl or heteroaryl group using a boronic acid or an ester thereof in the presence of a suitable base and a suitable metal catalyst in an inert solvent.
  • the solvent used may be the same as that used in the above step A-1a.
  • the base used may be the same as that used in the above step A-1a, and metal alkoxides such as sodium tert-butoxide and potassium tert-butoxide may also be used.
  • the metal catalyst used is not particularly limited as long as it is one used in a known method, but preferred examples include palladium catalysts such as tetrakis(triphenylphosphine)palladium, bis(tri-tert-butylphosphine)palladium, [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride, bis(dibenzylideneacetone)palladium, tris(dibenzylideneacetone)dipalladium, bis[1,2-bis(diphenylphosphino)ethane]palladium, (2-dicyclohexylphosphino-2'4'6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate, chloro(2-dicyclohexylphosphino-2',4'
  • the boronic acid to be used is not particularly limited, but examples thereof include phenylboronic acid, 3-chlorophenylboronic acid, and 3,5-difluorophenylboronic acid.
  • the boronic acid ester used is not particularly limited, but examples thereof include 3-cyclopropylphenylboronic acid pinacol ester.
  • the reaction temperature varies depending on the starting compounds, reagents, etc., but is usually from 0°C to 150°C, preferably from 20°C to 120°C.
  • the reaction time varies depending on the starting compounds, reagents, etc., but is usually from 5 minutes to 24 hours, preferably from 10 minutes to 12 hours. After completion of the reaction, the target compound of this reaction can be obtained, for example, through steps such as concentration, separation, and drying in the same manner as in the above-mentioned Step A-1a, and may be further purified by a conventional method, if necessary.
  • Step A-1e2 is carried out by converting the bromine atom on the aryl or heteroaryl ring to a boronic ester, followed by reaction with an aryl or heteroaryl halide.
  • step A-1e2a a reaction for converting a bromine atom on an aryl or heteroaryl ring to a boronic acid ester
  • step A-1e2b a reaction for converting a boronic acid ester and an aryl or heteroaryl halide to a biaryl compound.
  • Step A-1e2a is a step of converting a bromine atom on an aryl or heteroaryl ring into a boronic acid ester using a boron compound in the presence of a suitable base and a suitable metal catalyst in an inert solvent.
  • the solvent used may be the same as that used in the above step A-1a.
  • the base used may be the same as that used in the above step A-1a, and metal alkoxides such as sodium tert-butoxide and potassium tert-butoxide may also be used.
  • the metal catalyst used may be the same as that used in the above step A-1e1.
  • the boron compound to be used includes bis(pinacolato)diboron, pinacolborane, and the like.
  • the reaction temperature varies depending on the starting compounds, reagents, etc., but is usually from 0°C to 150°C, preferably from 20°C to 120°C.
  • the reaction time varies depending on the starting compounds, reagents, etc., but is usually from 5 minutes to 24 hours, preferably from 10 minutes to 12 hours.
  • the target compound of this reaction can be obtained, for example, through steps such as concentration, separation, and drying in the same manner as in the above-mentioned Step A-1a, and may be further purified by a conventional method, if necessary.
  • Step A-1e2b is a step of converting the boronic ester into an aryl or heteroaryl group using an aryl or heteroaryl halide in the presence of a suitable base in an inert solvent and in the presence of a suitable metal catalyst.
  • the solvent used may be the same as that used in the above step A-1a.
  • the base used may be the same as that used in the above step A-1a, and metal alkoxides such as sodium tert-butoxide and potassium tert-butoxide may also be used.
  • the metal catalyst used may be the same as that used in the above step A-1e1.
  • the aryl halide used may, for example, be 1-bromo-3-(difluoromethyl)-5-fluorobenzene.
  • the heteroaryl halides used include 2,6-dichloropyridine, 2-bromo-6-cyclopropylpyridine, and the like.
  • the reaction temperature varies depending on the starting compounds, reagents, etc., but is usually from 0°C to 150°C, preferably from 20°C to 120°C.
  • the reaction time varies depending on the starting compounds, reagents, etc., but is usually from 5 minutes to 24 hours, preferably from 10 minutes to 12 hours.
  • the target compound of the reaction can be obtained, for example, by concentrating the reaction mixture, adding an organic solvent such as ethyl acetate, washing with water, separating the organic layer containing the target compound, drying it with anhydrous sodium sulfate or the like, and then distilling off the solvent. If necessary, the resulting compound can be further purified by a conventional method such as recrystallization, reprecipitation, silica gel column chromatography, and the like.
  • This step involves reducing an alkene using hydrogen in the presence of a suitable metal catalyst in an inert solvent.
  • the solvent used may be the same as that used in the above step A-1a.
  • the metal catalyst to be used is not particularly limited, but preferred examples include metal catalysts such as palladium-activated carbon, platinum-activated carbon, nickel, and osmium-activated carbon.
  • the hydrogen source used may include hydrogen gas, ammonium formate, hydrazine, and the like.
  • the reaction temperature varies depending on the starting compounds, reagents, etc., but is usually from -10°C to 150°C, preferably from 0°C to 80°C.
  • the reaction time varies depending on the starting compounds, reagents, etc., but is usually from 5 minutes to 24 hours, preferably from 10 minutes to 12 hours.
  • the target compound of this reaction can be obtained, for example, through steps such as concentration, separation, and drying in the same manner as in the above-mentioned Step A-1a, and may be further purified by a conventional method, if necessary.
  • a conventional method if necessary.
  • Step A-2 is a step for producing a compound represented by general formula (4) from a compound represented by general formula (3).
  • a step for removing the tert-butoxycarbonyl group of a compound represented by general formula (3) using an appropriate acid in an inert solvent is described, but the method is not limited thereto.
  • the solvent used may be the same as that used in the above step A-1a.
  • the acid used is not particularly limited as long as it is an acid used in ordinary reactions, and preferred examples include inorganic acids such as hydrochloric acid, sulfuric acid, and nitric acid; and organic acids such as trifluoroacetic acid.
  • the reaction temperature varies depending on the starting compounds, reagents, etc., but is usually from -10°C to 100°C, preferably from 0°C to 50°C.
  • the reaction time varies depending on the starting compounds, reagents, etc., but is usually from 5 minutes to 24 hours, preferably from 10 minutes to 6 hours. After completion of the reaction, the target compound of this reaction can be obtained, for example, through steps such as concentration, separation, and drying in the same manner as in the above-mentioned Step A-1a, and may be further purified by a conventional method, if necessary.
  • Step A-3 is a step for producing a compound represented by general formula (1) from a compound represented by general formula (4).
  • Essential reactions include step A-3a: a reaction for converting the compound represented by general formula (4) to an amide, urea, or carbamate compound.
  • step A-3b a reaction for solvolyzing an ester
  • step A-3c a reaction for converting pyruvic acid amide to deuterated lactic acid amide can be added as necessary.
  • Step A-3a This step is a step of converting a compound represented by general formula (4) into an amide, urea, or carbamate compound.
  • a method of using an acid chloride, an isocyanate, a chloroformate, or di-tert-butyl dicarbonate in the presence or absence of a suitable base with a compound represented by general formula (4) (Step A-3a1), or a method of amidating a compound represented by general formula (4) and a carboxylic acid using a suitable condensing agent (Step A-3a2) will be described, but the present invention is not limited thereto.
  • This step is a step of converting the compound represented by the general formula (4) into an amide, urea or carbamate compound using an acid chloride, an isocyanate or a chloroformate in an inert solvent in the presence or absence of a suitable base.
  • the solvent used may be the same as that used in the above step A-1a.
  • the base used may be the same as that used in the above step A-1a.
  • the acid chloride used is not particularly limited as long as it is one that is used in ordinary reactions, and examples thereof include carboxylic acid chlorides such as acetyl chloride.
  • the isocyanate used is not particularly limited as long as it is one that is used in ordinary reactions, and examples thereof include methyl isocyanate.
  • the chloroformate used is not particularly limited as long as it is one that is used in ordinary reactions, and examples thereof include ethyl chloroformate.
  • the reaction temperature varies depending on the starting compounds, reagents, etc., but is usually from -20°C to 120°C, preferably from 0°C to 50°C.
  • the reaction time varies depending on the starting compounds, reagents, etc., but is usually from 5 minutes to 48 hours, preferably from 10 minutes to 24 hours.
  • the target compound of this reaction can be obtained, for example, through steps such as concentration, separation, and drying in the same manner as in the above-mentioned Step A-1a, and may be further purified by a conventional method, if necessary.
  • Step A-3a2 This step is a step of condensing the compound represented by formula (4) with a carboxylic acid, and is carried out in an inert solvent in the presence or absence of a base using a condensing agent.
  • the solvent used may be the same as that used in the above step A-1a.
  • the base used may be the same as that used in the above step A-1a.
  • the condensation agent used is not particularly limited as long as it is a condensation agent used to form an amide bond (for example, the methods described in Masakazu Kusumoto et al., Experimental Science Lectures IV; Chemical Society of Japan; Maruzen, 1990; Nobuo Izumiya et al., Fundamentals and Experiments of Peptide Synthesis; Maruzen, 1985, etc.), and is preferably O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), O-(benzotriazol-1-yl)- N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU), 2-(1H-benzotriazol-1-yl)-1,1,3,3-
  • fluorocarbons examples include bromo(triazol-1-yloxy)(tripyrrolidin-1-yl)phosphonium hexafluorophosphate (PyBOP), bromo(tripyrrolidin-1-yl)phosphonium hexafluorophosphate (PyBrOP), 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMT-MM), 2-chloro-4,6-dimethoxy-1,3,5-triazine (DMT), etc.
  • 1-hydroxybenzotriazole (HOBT), N,N-dimethylaminopyridine, etc. may be added as an additive.
  • the reaction temperature varies depending on the starting compounds, reagents, etc., but is usually from -10°C to 150°C, preferably from 0°C to 100°C.
  • the reaction time varies depending on the starting compounds, reagents, etc., but is usually from 5 minutes to 48 hours, preferably from 10 minutes to 24 hours.
  • the target compound of this reaction can be obtained, for example, through steps such as concentration, separation, and drying in the same manner as in the above-mentioned Step A-1a, and may be further purified by a conventional method, if necessary.
  • An optically active compound represented by the general formula (1) can be obtained by column chromatography using a chiral column.
  • Step A-3b This step is a step of solvolyzing a carboxylic acid ester contained in R 13 of the compound represented by general formula (1) in an inert solvent in the presence of a suitable base.
  • the solvent used may be the same as that used in the above step A-1a.
  • the base used may be the same as that used in the above step A-1a.
  • the reaction temperature varies depending on the starting compounds, reagents, etc., but is usually from -10°C to 100°C, preferably from 0°C to 60°C.
  • the reaction time varies depending on the starting compounds, reagents, etc., but is usually from 5 minutes to 48 hours, preferably from 10 minutes to 24 hours.
  • the target compound of this reaction can be obtained, for example, through steps such as concentration, separation, and drying in the same manner as in Step A-1a above, and may be further purified by a conventional method, if necessary.
  • An optically active compound represented by formula (1) can be obtained by column chromatography using a chiral column.
  • Step A-3c is a step of converting pyruvic acid amide contained in the compound represented by the general formula (1) into deuterated lactic acid amide.
  • step A-3c1 a reaction of converting a ketone to an alcohol using a deuterated reducing agent. If necessary, step A-3c2: a reaction of deuterizing a methyl group can be added before step A-3c1.
  • Step A-3c1 This step involves converting a ketone into an alcohol in the presence of a suitable deuterated reducing agent in an inert solvent.
  • the solvent used may be the same as that used in the above step A-1a.
  • the deuterated reducing agent used is not particularly limited as long as it is one that is used in ordinary reactions, and examples thereof include sodium borodeuteride, lithium aluminum deuteride, deuterium, and sodium deuterium formate.
  • the reaction temperature varies depending on the starting compounds, reagents, etc., but is usually from -20°C to 90°C, preferably from 0°C to 50°C.
  • the reaction time varies depending on the starting compounds, reagents, etc., but is usually from 5 minutes to 48 hours, preferably from 10 minutes to 24 hours.
  • the target compound of this reaction can be obtained, for example, through steps such as concentration, separation, and drying in the same manner as in the above-mentioned Step A-1a, and may be further purified by a conventional method, if necessary.
  • An optically active compound represented by formula (1) can be obtained by column chromatography using a chiral column.
  • This step involves deuterizing the methyl group of pyruvic acid amide in an inert solvent in the presence of a suitable base.
  • the solvent used may be the same as that used in the above step A-1a.
  • the base used may be the same as that used in the above step A-1a.
  • the reaction temperature varies depending on the starting compounds, reagents, etc., but is usually from -10°C to 100°C, preferably from 0°C to 60°C.
  • the reaction time varies depending on the starting compounds, reagents, etc., but is usually from 5 minutes to 72 hours, preferably from 10 minutes to 24 hours. After completion of the reaction, the target compound of this reaction can be subjected to the subsequent reaction without purification.
  • the compound of the present invention represented by general formula (1) can also be obtained by the method described below.
  • Method B is a method for producing a compound represented by general formula (1) from a compound represented by general formula (2).
  • R13 represents R2 or a precursor thereof
  • R14 represents R1 or a halogen atom.
  • Step B-1 This step is a step of producing a compound represented by general formula (5) by condensing a compound represented by general formula (2) with an alkyl bromide, and is carried out in accordance with step A-1a.
  • Step B-2 is a step for producing a compound represented by the general formula (6) from a compound represented by the general formula (5).
  • step B-2a a decarboxylation reaction accompanied by the elimination of the tert-butoxycarbonyl group
  • step B-2b a reaction for conversion to an amide or carbamate.
  • Step B-2a This step involves decarboxylation of a ⁇ -ketoester using an acid, which is accompanied by elimination of the tert-butoxycarbonyl group.
  • the solvent used may be the same as that used in the above step A-1a.
  • the acid to be used is not particularly limited as long as it is an acid that is usually used in reactions, and preferable examples include inorganic acids such as hydrochloric acid, sulfuric acid, and nitric acid.
  • the reaction temperature varies depending on the starting compounds, reagents, etc., but is usually from 0°C to 160°C, preferably from 80°C to 140°C.
  • the reaction time varies depending on the starting compounds, reagents, etc., but is usually from 5 minutes to 96 hours, preferably from 1 hour to 48 hours.
  • the target compound of the reaction can be obtained, for example, by distilling off the solvent from the reaction mixture. If necessary, the resulting compound can be further purified by a conventional method such as recrystallization, reprecipitation, silica gel column chromatography, and the like.
  • Step B-2b This step is a conversion step to a compound represented by formula (6) and is carried out in accordance with Step A-3a1.
  • Step B-3 is a step for producing a compound represented by the general formula (1) from a compound represented by the general formula (6).
  • Essential reactions include step B-3a: a reaction for converting a ketone to an amine, and step B-3b: a reaction for sulfonylation or sulfamoylation of an amine.
  • step B-3c a reaction for converting a bromine atom to an aryl group or heteroaryl group
  • step B-3d a reaction for solvolyzing an ester can be added as necessary.
  • Step B-3a This step is a step of converting a ketone to an oxime, followed by reduction to an amine, and is carried out in accordance with step A-1c.
  • Step B-3b This step is a step for sulfonylation or sulfamoylation of an amine, and is carried out in accordance with Step A-1d.
  • Step B-3c This step is a step of converting a bromine atom on an aryl ring or heteroaryl ring into an aryl group or heteroaryl group, and is carried out in accordance with step A-1e.
  • Step B-3d This step is a step of solvolyzing the carboxylate contained in R 13 of the compound represented by general formula (1), and is carried out in accordance with step A-3b.
  • the compound of the present invention represented by general formula (1) can also be obtained by the method described below.
  • Method C is a method for producing a compound represented by general formula (1) from a compound represented by general formula (2).
  • R 1 to R 6 and Z are synonymous with those defined above, and R 13 represents R 2 or a precursor thereof.
  • This step is a step for producing a compound represented by the general formula (7) by a substitution reaction between a compound represented by the general formula (2) and an alkyl bromide, and is carried out in accordance with Step A-1a.
  • Step C-2 is a step of producing a compound represented by general formula (8) from a compound represented by general formula (7) by decarboxylation reaction, and is carried out in accordance with Step A-1b.
  • Step C-3 is a step for producing a compound represented by the general formula (9) from a compound represented by the general formula (8).
  • step C-3a elimination of the tert-butoxycarbonyl group
  • step C-3b conversion to an amide or carbamate
  • step C-3c conversion of a ketone to an amine
  • step C-3d sulfonylation or sulfamoylation of an amine.
  • Step C-3a is a step of removing the tert-butoxycarbonyl group using an appropriate acid, and is carried out in accordance with Step A-2.
  • Step C-3b This step is a conversion step to a compound represented by formula (9) and is carried out in accordance with Step A-3a1.
  • This step is a step of converting a ketone to an oxime, followed by reduction to an amine, and is carried out in accordance with step A-1c.
  • Step C-3d This step is a step for sulfonylation or sulfamoylation of an amine, and is carried out in accordance with Step A-1d.
  • Step C-4 is a step for producing a compound represented by the general formula (1) from a compound represented by the general formula (9).
  • step C-4a a reaction to convert a bromine atom on an aryl or heteroaryl ring to an aryl or heteroaryl group.
  • step C-4b a reaction to solvolyze an ester can be added as necessary.
  • Step C-4a is a step of converting a bromine atom on an aryl ring or heteroaryl ring into an aryl group or heteroaryl group, and is carried out in accordance with step A-1e.
  • Step C-4b is a step of solvolyzing the carboxylate contained in R 13 of the compound of formula (1), and is carried out in accordance with step A-3b.
  • splitting patterns were indicated as follows: singlet (s), doublet (d), double doublet (dd), double triplet (dt), triplet (t), triple doublet (td), quartet (q), multiplet (m), and broad (br).
  • single diastereomer means that the ratio of a specific diastereomer (which may be a racemate) to a stereoisomer other than the specific diastereomer is 20:1 (20/1) or more
  • Example 1 N- ⁇ (3S,4S)-2-(2-hydroxy-2-methylpropanoyl)-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • a mixture of 1,3-difluoro-5-(2-fluoro-3-methylphenyl)benzene (CAS registration number: 2409648-15-1, 50 g), N-bromosuccinimide (50 g), azobisisobutyronitrile (4.0 g), and acetonitrile (500 mL) was degassed and then stirred at 80°C under a nitrogen atmosphere for 6 hours.
  • Example 2 N'- ⁇ (3S,4S)-2-(2-hydroxy-2-methylpropanoyl)-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ -N,N-dimethylsulfamide (2A) 1- ⁇ 4-(hydroxyimino)-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-2-yl ⁇ -2-methyl-1-oxopropan-2-yl acetate: Hydroxylamine hydrochloride (30 g) and sodium acetate (44 g) were added to a mixture of the compound (55 g) synthesized in Example 1C and ethanol (700 mL) at room temperature, and then the mixture was stirred at 80°C for 2 hours. The mixture was diluted with ethyl acetate, washed with
  • Example 3 N- ⁇ (3S,4S)-2-(2-hydroxy-2-methylpropanoyl)-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ ethanesulfonamide (3A) 1- ⁇ (3S,4S)-4-[(ethylsulfonyl)amino]-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-2-yl ⁇ -2-methyl-1-oxopropan-2-yl acetate
  • the compound synthesized in Example 2C (1.00 g), triethylamine (0.602 mL) and tetrahydrofuran (20 mL) were mixed and added with ethanesulfonyl chloride (0.267 mL) under ice cooling, and stirred at room temperature
  • Example 4B N- ⁇ (3S,4S)-2-(2-hydroxy-2-methylpropanoyl)-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ propane-2-sulfonamide
  • the compound synthesized in Example 4A (15 mg), water (0.3 mL), and methanol (1.5 mL) were mixed and added with lithium hydroxide monohydrate (4.0 mg) at room temperature and stirred for 12 hours.
  • Example 5 N- ⁇ 2-(bicyclo[1.1.1]pentan-1-ylcarbonyl)-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ ethanesulfonamide (5A) 3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-one hydrochloride: Hydrochloric acid (12 M, 320 mL) was added to a mixture of the compound (63 g) synthesized in Example 1B, lithium chloride (5.4 g), and acetic acid (320 mL) at room temperature, and the mixture was stirred at 100° C. for 12 hours. The solvent was distilled off under reduced pressure to obtain 55 g of the crude title compound.
  • Example 5C tert-Butyl 4-(hydroxyimino)-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptane-2-carboxylate
  • the compound synthesized in Example 5B (11 g) was used in the same manner as in Example 2A to obtain 12 g of the crude title compound.
  • Example 6 1-Fluoro-N- ⁇ 2-(2-hydroxy-2-methylpropanoyl)-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • 6A tert-Butyl 4- ⁇ [(fluoromethyl)sulfonyl]amino ⁇ -3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptane-2-carboxylate
  • the title compound 40 mg, yield: 65% was obtained as a single diastereomer and a single enantiomer in the same manner as in Example 5F.
  • the mixture was diluted with ethyl acetate, washed with water and saturated saline, and then dried over sodium sulfate. After filtration, the solvent was distilled off under reduced pressure to obtain 50 mg of the crude title compound as a single diastereomer and a single enantiomer.
  • Example 7 4-[(Ethylsulfonyl)amino]-N,N-dimethyl-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptane-2-carboxamide (7A) 4-[(ethylsulfonyl)amino]-N,N-dimethyl-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptane-2-carboxamide
  • the compound synthesized in Example 5G 50 mg
  • triethylamine (33 mg) and tetrahydrofuran 5.0 mL
  • Triethylamine (66 mg) and 4-nitrophenyl chloroformate (55 mg) were added to a mixture of the compound (100 mg) synthesized in Example 5G and dichloromethane (8.0 mL) at 0°C, and the mixture was stirred at room temperature for 12 hours.
  • the solvent was removed under reduced pressure, and the residue was added to a mixture of azetidine hydrochloride (89 mg), N,N-diisopropylethylamine (84 mg) and N,N-dimethylformamide (5.0 mL), and the mixture was stirred at 80°C for 12 hours. Water was added, and the mixture was extracted twice with ethyl acetate, and the combined organic layer was washed with saturated saline.
  • Example 10 N-[(3S,4S)-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-(2-hydroxy-2-methylpropanoyl)-2-azabicyclo[3.1.1]heptan-4-yl]methanesulfonamide (10A) 1- ⁇ (3S,4S)-3-[(2-fluoro[biphenyl]-3-yl)methyl]-4-[(methylsulfonyl)amino]-2-azabicyclo[3.1.1]heptan-2-yl ⁇ -2-methyl-1-oxopropan-2-yl acetate Using the compound (50 mg) synthesized in Example 8I and phenylboronic acid (12 mg), 40 mg (yield: 78%) of the title compound was obtained as a single diastereomer and a single enantiomer in the same manner as in Example 8J.
  • Example 11 N-[(3S,4S)-3-[(2-fluoro-3'-methyl[biphenyl]-3-yl)methyl]-2-(2-hydroxy-2-methylpropanoyl)-2-azabicyclo[3.1.1]heptan-4-yl]methanesulfonamide (11A) 1- ⁇ (3S,4S)-3-[(2-fluoro-3'-methyl[biphenyl]-3-yl)methyl]-4-[(methylsulfonyl)amino]-2-azabicyclo[3.1.1]heptan-2-yl ⁇ -2-methyl-1-oxopropan-2-yl acetate Using the compound (50 mg) synthesized in Example 8I and 3-methylphenylboronic acid (16 mg), the title compound was obtained as a single diastereomer and a single enantiomer in a similar manner to Example 8J (44 mg, yield: 86%).
  • Example 12 N- ⁇ 5-fluoro-2-(2-hydroxy-2-methylpropanoyl)-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide (12A) Methyl 3- ⁇ trans-3-[(tert-butoxycarbonyl)amino]-1-fluorocyclobutyl ⁇ -3-oxopropanoate trans-3-(tert-butoxycarbonylamino)-1-fluoro-cyclobutanecarboxylic acid (CAS registration number: 2408768-09-0, 20 g), 2,2-dimethyl-1,3-dioxane-4,6-dione (15 g), N, N-dimethylaminopyridine (16 g), dichloromethane (200 mL) was mixed with 1-(3-dimethylaminopropyl)-3-ethylcarbodi
  • Triethylamine (0.433 mL) and 2-acetoxyisobutyryl chloride (0.136 mL) were added to a mixture of the obtained residue and tetrahydrofuran (4.11 mL) at 0°C, and the mixture was stirred at room temperature for 2 hours.
  • a saturated aqueous ammonium chloride solution and water were added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline and dried over anhydrous sodium sulfate.
  • Example 14 N-[(3S,4S)-3-[(2-fluoro-3'-methoxy[biphenyl]-3-yl)methyl]-2-(2-hydroxy-2-methylpropanoyl)-2-azabicyclo[3.1.1]heptan-4-yl]methanesulfonamide (14A) 1- ⁇ (3S,4S)-3-[(2-fluoro-3'-methoxy[biphenyl]-3-yl)methyl]-4-[(methylsulfonyl)amino]-2-azabicyclo[3.1.1]heptan-2-yl ⁇ -2-methyl-1-oxopropan-2-yl acetate Using the compound (50 mg) synthesized in Example 8I and 3-methoxyphenylboronic acid (20 mg), the title compound was obtained in a similar manner to Example 8J, giving 30 mg (yield: 57%) as a single diastereomer and a single enantiomer.
  • Example 15 N- ⁇ (3S,4S)-2-[(2S)-2-hydroxypropanoyl]-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • 15A tert-Butyl (3S,4S)-4-[(methylsulfonyl)amino]-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptane-2-carboxylate
  • Example 8G Using the compound synthesized in Example 8G (96.0 mg) and 3,5-difluorophenylboronic acid (48 mg), 99 mg (yield: 96%) of the title compound was obtained as a single diastereomer and a single enantiomer in the same manner as in Example 8J.
  • Example 17 N- ⁇ (3S,4S)-2-[(2R)-tetrahydrofuran-2-ylcarbonyl]-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • (17A) N- ⁇ (3S,4S)-2-[(2R)-tetrahydrofuran-2-ylcarbonyl]-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • the title compound 27 mg, yield: 47%) was obtained as a single diastereomer and a single enantiomer in the same manner as in
  • Example 18 N-[(3S,4S)-3- ⁇ [2-fluoro-3'-(trifluoromethyl)[biphenyl]-3-yl]methyl ⁇ -2-(2-hydroxy-2-methylpropanoyl)-2-azabicyclo[3.1.1]heptan-4-yl]methanesulfonamide (18A) 1- ⁇ (3S,4S)-3- ⁇ [2-fluoro-3'-(trifluoromethyl)[biphenyl]-3-yl]methyl ⁇ -4-[(methylsulfonyl)amino]-2-azabicyclo[3.1.1]heptan-2-yl ⁇ -2-methyl-1-oxopropan-2-yl acetate Using the compound synthesized in Example 8I (50 mg) and 3-trifluoromethylphenylboronic acid (24 mg), 60 mg of the crude title compound was obtained as a single diastereomer and a single enantiomer by a method similar to that of Example 8J.
  • Example 21 N-[(3S,4S)-3-[3-(6-chloropyridin-2-yl)-2-fluorobenzyl]-2-(2-hydroxy-2-methylpropanoyl)-2-azabicyclo[3.1.1]heptan-4-yl]methanesulfonamide (21A) tert-Butyl (3S,4S)-3-[2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-4-[(methylsulfonyl)amino]-2-azabicyclo[3.1.1]heptane-2-carboxylate.
  • Example 8G The compound synthesized in Example 8G (200 mg), bis(pinacolato)diboron (220 mg), potassium acetate (65 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (35 mg) and 1,4-dioxane (5.0 mL) were degassed and stirred for 2 hours at 100°C under a nitrogen atmosphere. After filtration, the solvent was distilled off under reduced pressure to obtain 110 mg of the crude title compound as a single diastereomer and a single enantiomer.
  • Example 21C N- ⁇ (3S,4S)-3-[3-(6-chloropyridin-2-yl)-2-fluorobenzyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide hydrochloride Using the compound synthesized in Example 21B (90 mg), 80 mg of the crude title compound was obtained as a single diastereomer and a single enantiomer in the same manner as in Example 8H.
  • Example 22 N-[2-(cyclopropylcarbonyl)-3- ⁇ [2-(3,5-difluorophenyl)-3-fluoropyridin-4-yl]methyl ⁇ -2-azabicyclo[3.1.1]heptan-4-yl]methanesulfonamide (22A) 2-(3,5-difluorophenyl)-3-fluoro-4-methylpyridine 2-Bromo-3-fluoro-4-methylpyridine (CAS registration number: 884494-37-5, 9.5 g), 3,5-difluorophenylboronic acid (10.5 g), water (5.0 mL) and 1,4-dioxane (100 mL) were mixed with potassium carbonate (14 g) and [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride (2.0 g) and stirred for 12 hours at 100°C under a nitrogen atmosphere.
  • Example 23 N- ⁇ (3S,4R)-5-fluoro-2-[(2R)-2-hydroxypropanoyl]-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide or N- ⁇ (3R,4S)-5-fluoro-2-[(2R)-2-hydroxypropanoyl]-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide (23A) 2-tert-butyl 3-methyl 3-(3-bromo-2-fluorobenzyl)-5-fluoro-4-oxo-2-azabicyclo[3.1.1]heptane-2,3-dicarboxylate The compound synthesized in Example 12C (2.42 g), 3-bro
  • Molybdenum oxide (VI) (167 mg) was added at room temperature, sodium borohydride (175 mg) was added in small portions, and the mixture was stirred at 45° C. for 4 hours.
  • sodium borohydride (175 mg) was added in small portions, and the mixture was stirred at 45° C. for 4 hours.
  • molybdenum oxide (VI) (1.18 g) was added at 0° C., sodium borohydride (1.24 g) was added in small portions, and the mixture was stirred at 45° C. for 4 hours.
  • molybdenum oxide (VI) (1.18 g) was added at 0° C., sodium borohydride (1.24 g) was added in small portions, and the mixture was stirred at 45° C. for 6 hours.
  • molybdenum oxide (VI) (1.18 g) was added at 0° C., sodium borohydride (1.24 g) was added in small portions, and the mixture was stirred at 45° C. for 2 hours.
  • Molybdenum(VI) oxide (1.18 g) was added thereto at room temperature, and sodium borohydride (1.24 g) was added in small portions, followed by stirring at 45°C for 5 hours.
  • Example 24 N- ⁇ (3S,4S)-3- ⁇ [3'-(difluoromethyl)-2-fluoro[biphenyl]-3-yl]methyl ⁇ -2-[(2R)-2-hydroxypropanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide (24A) tert-Butyl (3S,4S)-3- ⁇ [3'-(difluoromethyl)-2-fluoro[biphenyl]-3-yl]methyl ⁇ -4-[(methylsulfonyl)amino]-2-azabicyclo[3.1.1]heptane-2-carboxylate Using the compound synthesized in Example 8G (100 mg) and 3-(difluoromethyl)phenylboronic acid (54 mg), 200 mg of the title compound mixed with by-products was obtained as a single diastereomer and a single enantiomer in the same manner as in Example 8J.
  • Phenylboronic acid (153 mg), (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate (44 mg), and tripotassium phosphate (667 mg) were added to a mixture of the compound (500 mg) synthesized in Example 8G and tetrahydrofuran (5.0 mL), and the mixture was degassed and stirred at 70°C under a nitrogen atmosphere for 1.5 hours.
  • Example 26 N- ⁇ (3S,4S)-2-[(2R)-2-hydroxybutanoyl]-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • 26A N- ⁇ (3S,4S)-2-[(2R)-2-hydroxybutanoyl]-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • Using the compound synthesized in Example 15B 100 mg
  • (R)-2-hydroxybutanoic acid 35 mg
  • 25 mg Yield: 23%) of the title compound was obtained as a single diastereomer and a single enantiomer in the same manner as in Example 5H.
  • Example 27 (3S,4S)-N-Methyl-4-[(methylsulfonyl)amino]-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptane-2-carboxamide
  • 27A (3S,4S)-N-methyl-4-[(methylsulfonyl)amino]-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptane-2-carboxamide
  • the compound synthesized in Example 15B 50 mg
  • tetrahydrofuran 2.0 mL
  • Triethylamine (0.047 mL), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (31 mg), (1R,2S)-2-fluorocyclopropane-1-carboxylic acid (8 mg) were added to a mixture of the compound (30.0 mg) synthesized in Example 15B and dichloromethane (2 mL), and the mixture was stirred at room temperature for 1 hour. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline and dried over anhydrous sodium sulfate.
  • Example 31 N- ⁇ (3S,4S)-3-[(3'-cyano-2,5'-difluoro[biphenyl]-3-yl)methyl]-2-[(2R)-2-hydroxypropanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide (31A) tert-Butyl (3S,4S)-3-[(3'-cyano-2,5'-difluoro[biphenyl]-3-yl)methyl]-4-[(methylsulfonyl)amino]-2-azabicyclo[3.1.1]heptane-2-carboxylate Using the compound synthesized in Example 8G (49.2 mg) and 3-cyano-5-fluorophenylboronic acid (25.5 mg), 62.4 mg (yield: 99%) of the title compound was obtained as a single diastereomer and a single enantiomer in the same manner as in Example 8J.
  • Example 31B N- ⁇ (3S,4S)-3-[(3'-cyano-2,5'-difluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide hydrochloride
  • the compound synthesized in Example 31A (62.4 mg) was added with hydrogen chloride 1,4-dioxane solution (4 M, 1.0 mL) at room temperature and stirred for 3 hours. The solvent was removed under reduced pressure and washed with ethyl acetate to obtain the title compound 37.0 mg (yield: 79%) as a single diastereomer and a single enantiomer.
  • Example 31C (2R)-1- ⁇ (3S,4S)-3-[(3'-cyano-2,5'-difluoro[biphenyl]-3-yl)methyl]-4-[(methylsulfonyl)amino]-2-azabicyclo[3.1.1]heptan-2-yl ⁇ -1-oxopropan-2-yl acetate
  • the compound synthesized in Example 31B (19.7 mg), (R)-2-acetoxypropanoic acid (0.0058 mL), and N,N-dimethylformamide (1.0 mL) were added to a mixture at room temperature with N,N-diisopropylethylamine (0.0227 mL), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (33.0 mg) and stirred for 1 hour.
  • Example 32 N- ⁇ (3S,4S)-3-[2-fluoro-3-(1-methyl-1H-pyrazol-3-yl)benzyl]-2-[(2R)-2-hydroxypropanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide (32A) tert-Butyl (3S,4S)-3-[2-fluoro-3-(1-methyl-1H-pyrazol-3-yl)benzyl]-4-[(methylsulfonyl)amino]-2-azabicyclo[3.1.1]heptane-2-carboxylate Using the compound (50.2 mg) synthesized in Example 8G and 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (32.8 mg), the title compound was obtained in a similar manner to Example 8J, as a single diastereomer and a single enantiomer,
  • Example 33 N- ⁇ (3S,4S)-2-[(1-cyanocyclopropyl)carbonyl]-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • 33A N- ⁇ (3S,4S)-2-[(1-cyanocyclopropyl)carbonyl]-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • the title compound (25.6 mg) was obtained as a single diastereomer and a single enantiomer (yield: quantitative) in the same manner as in Example 31C.
  • Example 34 N- ⁇ (3S,4S)-2-(hydroxyacetyl)-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide (34A) 2- ⁇ (3S,4S)-4-[(methylsulfonyl)amino]-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-2-yl ⁇ -2-oxoethyl acetate 2-acetoxyacetyl chloride (18 mg) was added to a mixture of the compound synthesized in Example 15B (50 mg), N,N-diisopropylethylamine (72 mg), and tetrahydrofuran (0.5 mL) and stirred at room temperature for 30 minutes.
  • Example 35 (3S,4S)-4-[(methylsulfonyl)amino]-N-(propan-2-yl)-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptane-2-carboxamide
  • 35A (3S,4S)-4-[(methylsulfonyl)amino]-N-(propan-2-yl)-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptane-2-carboxamide
  • the compound synthesized in Example 15B (30 mg), N,N-diisopropylethylamine (43 mg), and tetrahydrofuran (0.5 mL) were mixed with isopropyl isocyanate (7 mg) and stirred at room temperature for 30 minutes.
  • Cyclopropanecarbonyl chloride (0.0235 mL) was added to a mixture of the compound synthesized in Example 23G (60.0 mg), N,N-diisopropylethylamine (0.0878 mL), and tetrahydrofuran (2.5 mL) at room temperature and stirred for 3 hours. The mixture was diluted with ethyl acetate, washed with water and saturated saline, and dried over sodium sulfate.
  • Example 38 N- ⁇ (3S,4S)-3-[3-(2,2-difluoro-1,3-benzodioxol-4-yl)-2-fluorobenzyl]-2-[(2R)-2-hydroxypropanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide (38A) tert-Butyl (3S,4S)-3-[3-(2,2-difluoro-1,3-benzodioxol-4-yl)-2-fluorobenzyl]-4-[(methylsulfonyl)amino]-2-azabicyclo[3.1.1]heptane-2-carboxylate Using the compound (100 mg) synthesized in Example 8G and (2,2-difluoro-1,3-benzodioxol-4-yl)boronic acid (50 mg), the title compound (100 mg, yield: 86%) was obtained as a single diastere
  • Example 38B N- ⁇ (3S,4S)-3-[3-(2,2-difluoro-1,3-benzodioxol-4-yl)-2-fluorobenzyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide hydrochloride Using the compound synthesized in Example 38A (100 mg), 75 mg of the crude title compound was obtained as a single diastereomer and a single enantiomer in the same manner as in Example 5G.
  • Example 39 (3S,4S)-N-(cyclopropylmethyl)-4-[(methylsulfonyl)amino]-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptane-2-carboxamide
  • 39A (3S,4S)-N-(cyclopropylmethyl)-4-[(methylsulfonyl)amino]-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptane-2-carboxamide
  • Cyclopropylmethylamine (16 mg), N,N-diisopropylethylamine (87 mg), and a dichloromethane (1.0 mL) solution of triphosgene (65 mg) was added to a mixture of dichloromethane (2.0 mL) at 0°C, and the mixture was stirred at
  • Example 40 N- ⁇ (3S,4S)-3-[(2,3'-difluoro[biphenyl]-3-yl)methyl]-2-[(2R)-2-hydroxypropanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide (40A) tert-Butyl (3S,4S)-3-[(2,3'-difluoro[biphenyl]-3-yl)methyl]-4-[(methylsulfonyl)amino]-2-azabicyclo[3.1.1]heptane-2-carboxylate Using the compound synthesized in Example 8G (150 mg) and 3-fluorophenylboronic acid (66 mg), 130 mg (yield: 84%) of the title compound was obtained as a single diastereomer and a single enantiomer in the same manner as in Example 8J.
  • Example 40B N- ⁇ (3S,4S)-3-[(2,3'-difluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide hydrochloride Using the compound synthesized in Example 40A (130 mg), the crude title compound (100 mg) was obtained as a single diastereomer and a single enantiomer in the same manner as in Example 5G.
  • Example 41 N- ⁇ (3S,4S)-3-[(3'-cyclopropyl-2-fluoro[biphenyl]-3-yl)methyl]-2-[(2R)-2-hydroxypropanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide (41A) tert-Butyl (3S,4S)-3-[(3'-cyclopropyl-2-fluoro[biphenyl]-3-yl)methyl]-4-[(methylsulfonyl)amino]-2-azabicyclo[3.1.1]heptane-2-carboxylate Using the compound synthesized in Example 8G (100 mg) and 2-(3-cyclopropylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (70 mg), 60 mg (yield: 56%) of the title compound was obtained as a single diastereomer and a single enanti
  • Example 41B N- ⁇ (3S,4S)-3-[(3'-cyclopropyl-2-fluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide hydrochloride Using the compound synthesized in Example 41A (60 mg), 40 mg of the crude title compound was obtained as a single diastereomer and a single enantiomer in the same manner as in Example 5G.
  • Example 42 N- ⁇ (3S,4S)-3- ⁇ [2-fluoro-3'-(trifluoromethoxy)[biphenyl]-3-yl]methyl ⁇ -2-[(2R)-2-hydroxypropanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide (42A) tert-Butyl (3S,4S)-3- ⁇ [2-fluoro-3'-(trifluoromethoxy)[biphenyl]-3-yl]methyl ⁇ -4-[(methylsulfonyl)amino]-2-azabicyclo[3.1.1]heptane-2-carboxylate.
  • Example 43 N- ⁇ (3S,4S)-3-[3-(6-cyclopropylpyridin-2-yl)-2-fluorobenzyl]-2-[(2R)-2-hydroxypropanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide (43A) tert-Butyl (3S,4S)-3-[3-(6-cyclopropylpyridin-2-yl)-2-fluorobenzyl]-4-[(methylsulfonyl)amino]-2-azabicyclo[3.1.1]heptane-2-carboxylate.
  • a mixture of the compound synthesized in Example 21A (60 mg), cesium carbonate (75 mg), 2-bromo-6-cyclopropylpyridine (CAS registration number: 1086381-26-1, 40 mg), (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate (6 mg), water (0.5 mL) and 1,4-dioxane (3.0 mL) was degassed and then stirred at 100°C for 2 hours under a nitrogen atmosphere.
  • Example 43B N- ⁇ (3S,4S)-3-[3-(6-cyclopropylpyridin-2-yl)-2-fluorobenzyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide hydrochloride Using the compound synthesized in Example 43A (50 mg), 40 mg of the crude title compound was obtained as a single diastereomer and a single enantiomer in the same manner as in Example 5G.
  • Example 44 N- ⁇ (3S,4S)-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-[(2R)-2-hydroxypropanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ cyclopropanesulfonamide (44A) tert-Butyl (3S,4S)-3-(3-bromo-2-fluorobenzyl)-4-[(cyclopropylsulfonyl)amino]-2-azabicyclo[3.1.1]heptane-2-carboxylate.
  • Cyclopropanesulfonyl chloride (0.0393 mL) was added to a mixture of the compound synthesized in Example 8F (110 mg), triethylamine (0.0764 mL), and tetrahydrofuran (2.3 mL) under ice cooling, and then stirred at room temperature for 1.5 hours.
  • 4-Dimethylaminopyridine (33.7 mg), triethylamine (0.0764 mL), and cyclopropanesulfonyl chloride (0.0393 mL) were added, and the mixture was stirred at 40° C. for 3 hours.
  • the mixture was diluted with ethyl acetate, washed with hydrochloric acid (1 M) and aqueous sodium bicarbonate, and dried over sodium sulfate. After filtration, the solvent was distilled off under reduced pressure to obtain 139 mg of the crude title compound as a single diastereomer and single enantiomer.
  • Phenylboronic acid 24 mg
  • potassium carbonate 50 mg
  • (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl) [2-(2'-amino-1,1'-biphenyl)] palladium (II) methanesulfonate 5.0 mg
  • the mixture was diluted with ethyl acetate, washed with water and saturated saline, and dried over sodium sulfate.
  • Example 44C N- ⁇ (3S,4S)-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ cyclopropanesulfonamide hydrochloride Using the compound synthesized in Example 44B (127 mg), the crude title compound (106 mg) was obtained as a single diastereomer and a single enantiomer in the same manner as in Example 8H.
  • the mixture was diluted with ethyl acetate, washed with hydrochloric acid (1 M), sodium bicarbonate water, and saturated saline, and dried over sodium sulfate. After filtration, the solvent was distilled off under reduced pressure to obtain 32.0 mg of the crude title compound as a single diastereomer and a single enantiomer.
  • Example 45 N-[(3S,4S)-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2- ⁇ [(1R,2R)-2-fluorocyclopropyl]carbonyl ⁇ -2-azabicyclo[3.1.1]heptan-4-yl]cyclopropanesulfonamide (45A) N-[(3S,4S)-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2- ⁇ [(1R,2R)-2-fluorocyclopropyl]carbonyl ⁇ -2-azabicyclo[3.1.1]heptan-4-yl]cyclopropanesulfonamide Using the compound (25.0 mg) synthesized in Example 44C and (1R,2R)-2-fluorocyclopropane-1-carboxylic acid (8.9 mg), the title compound (26.6 mg, yield: 96%) was obtained as a single diastereomer and a single enantiomer in the
  • Example 46 N- ⁇ (3S,4R)-2-acetyl-3-[(3'-chloro-2-fluoro[biphenyl]-3-yl)methyl]-5-fluoro-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide (46A) tert-Butyl 4-amino-3-(3-bromo-2-fluorobenzyl)-5-fluoro-2-azabicyclo[3.1.1]heptane-2-carboxylate Sodium borohydride (50 g) was added to a mixture of the compound synthesized in Example 23C (1.5 g), molybdenum (VI) oxide (1.0 g) and methanol (150 mL) at 0° C., and the mixture was stirred at room temperature for 23 hours.
  • VI molybdenum
  • methanol 150 mL
  • Example 46B tert-Butyl (3S,4R)-4-amino-3-(3-bromo-2-fluorobenzyl)-5-fluoro-2-azabicyclo[3.1.1]heptane-2-carboxylate
  • reaction solution was poured into sodium bicarbonate water, extracted with ethyl acetate, and then washed with saturated saline. The mixture was dried over sodium sulfate, filtered, and the solvent was removed under reduced pressure to obtain 150 mg of the crude title compound as a single diastereomer and a single enantiomer.
  • Example 47 N- ⁇ (3S,4S)-3- ⁇ 3-[6-(difluoromethyl)pyridin-2-yl]-2-fluorobenzyl ⁇ -2-[(2R)-2-hydroxypropanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide (47A) tert-Butyl (3S,4S)-3- ⁇ 3-[6-(difluoromethyl)pyridin-2-yl]-2-fluorobenzyl ⁇ -4-[(methylsulfonyl)amino]-2-azabicyclo[3.1.1]heptane-2-carboxylate.
  • Example 21A A mixture of the compound synthesized in Example 21A (109 mg), cesium carbonate (135 mg), 2-bromo-6-(difluoromethyl)pyridine (CAS registration number: 872365-91-8, 43 mg), (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate (18 mg), water (0.8 mL) and 1,4-dioxane (4.0 mL) was degassed and then stirred at 100°C for 2 hours under a nitrogen atmosphere.
  • Example 47B N-[(3S,4S)-3- ⁇ 3-[6-(difluoromethyl)pyridin-2-yl]-2-fluorobenzyl ⁇ -2-azabicyclo[3.1.1]heptan-4-yl]methanesulfonamide hydrochloride Using the compound synthesized in Example 47A (50 mg), 44 mg of the crude title compound was obtained as a single diastereomer and a single enantiomer in the same manner as in Example 5G.
  • Example 47D N- ⁇ (3S,4S)-3- ⁇ 3-[6-(difluoromethyl)pyridin-2-yl]-2-fluorobenzyl ⁇ -2-[(2R)-2-hydroxypropanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • the compound synthesized in Example 47C 48 mg
  • tetrahydrofuran 2.0 mL
  • the mixture was diluted with ethyl acetate, washed with water and saturated saline, and then dried over sodium sulfate.
  • Example 48 N- ⁇ (3S,4S)-2-[(2R)-2-methoxypropanoyl]-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • 48A N- ⁇ (3S,4S)-2-[(2R)-2-methoxypropanoyl]-3-[(2,3',5'-trifluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • Example 49 N-[(3S,4R)-3- ⁇ [3'-(difluoromethyl)-2-fluoro[biphenyl]-3-yl]methyl ⁇ -5-fluoro-2-(2-hydroxy-2-methylpropanoyl)-2-azabicyclo[3.1.1]heptan-4-yl]methanesulfonamide (49A) tert-Butyl (3S,4R)-3- ⁇ [3'-(difluoromethyl)-2-fluoro[biphenyl]-3-yl]methyl ⁇ -5-fluoro-4-[(methylsulfonyl)amino]-2-azabicyclo[3.1.1]heptane-2-carboxylate Using the compound synthesized in Example 46C (40 mg) and 3-(difluoromethyl)phenylboronic acid (20 mg), the title compound (20 mg) was obtained as a single diastereomer and a single enantiomer (yield: 46%) in the same manner
  • Example 50 N-[(3S,4R)-5-fluoro-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-(2-hydroxy-2-methylpropanoyl)-2-azabicyclo[3.1.1]heptan-4-yl]methanesulfonamide (50A) tert-Butyl (3S,4R)-5-fluoro-3-[(2-fluoro[biphenyl]-3-yl)methyl]-4-[(methylsulfonyl)amino]-2-azabicyclo[3.1.1]heptane-2-carboxylate Using the compound synthesized in Example 46C (120 mg) and phenylboronic acid (48 mg), the title compound (60 mg, yield: 50%) was obtained as a single diastereomer and a single enantiomer in the same manner as in Example 8J.
  • Example 51 N-[(3S,4S)-3- ⁇ [3'-(difluoromethyl)-2,5'-difluoro[biphenyl]-3-yl]methyl ⁇ -2-(2-hydroxy-2-methylpropanoyl)-2-azabicyclo[3.1.1]heptan-4-yl]methanesulfonamide (51A) tert-butyl (3S,4S)-3- ⁇ [3'-(difluoromethyl)-2,5'-difluoro[biphenyl]-3-yl]methyl ⁇ -4-[(methylsulfonyl)amino]-2-azabicyclo[3.1.1]heptane-2-carboxylate
  • the compound synthesized in Example 21A 100 mg
  • cesium carbonate 124 mg
  • 1-bromo-3-(difluoromethyl)-5-fluorobenzene 51 mg
  • Example 51B N-[(3S,4S)-3- ⁇ [3'-(difluoromethyl)-2,5'-difluoro[biphenyl]-3-yl]methyl ⁇ -2-azabicyclo[3.1.1]heptan-4-yl]methanesulfonamide hydrochloride Using the compound synthesized in Example 51A (50 mg), 60 mg of the crude title compound was obtained as a single diastereomer and a single enantiomer in the same manner as in Example 5G.
  • Example 52 N-[(3S,4S)-3-[(3'-chloro-2,5'-difluoro[biphenyl]-3-yl)methyl]-2-(2-hydroxy-2-methylpropanoyl)-2-azabicyclo[3.1.1]heptan-4-yl]methanesulfonamide (52A) tert-Butyl (3S,4S)-3-[(3'-chloro-2,5'-difluoro[biphenyl]-3-yl)methyl]-4-[(methylsulfonyl)amino]-2-azabicyclo[3.1.1]heptane-2-carboxylate Using the compound synthesized in Example 8G (100 mg) and 3-chloro-5-fluorophenylboronic acid (55 mg), 35 mg (yield: 32%) of the title compound was obtained as a single diastereomer and a single enantiomer in the same manner as in Example 8J.
  • Example 52B N- ⁇ (3S,4S)-3-[(3'-chloro-2,5'-difluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide hydrochloride Using the compound synthesized in Example 52A (30 mg), the crude title compound (26 mg) was obtained as a single diastereomer and a single enantiomer in the same manner as in Example 5G.
  • Example 53 N- ⁇ (3S,4R)-5-fluoro-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-[(2R)-2-hydroxypropanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide (53A) (2R)-1- ⁇ (3S,4R)-5-fluoro-3-[(2-fluoro[biphenyl]-3-yl)methyl]-4-[(methylsulfonyl)amino]-2-azabicyclo[3.1.1]heptan-2-yl ⁇ -1-oxopropan-2-yl acetate.
  • Example 50B The compound synthesized in Example 50B (20 mg) and tetrahydrofuran (1.0 mL) were mixed at room temperature with N,N-diisopropylethylamine (60 mg) and (R)-2-acetoxypropionic acid chloride (12 mg) and stirred for 30 minutes. The mixture was diluted with ethyl acetate, washed with water and saturated saline, and then dried over sodium sulfate. After filtration, the solvent was distilled off under reduced pressure to obtain 20 mg of the crude title compound as a single diastereomer and a single enantiomer.
  • Example 54 N- ⁇ (3S,4S)-3- ⁇ [2-fluoro(2',3',4',5', 6'- 2H5 )[biphenyl]-3-yl]methyl ⁇ -2-[(2R)-2-hydroxypropanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • 54A tert-Butyl (3S,4S)-3- ⁇ [2-fluoro(2',3',4',5',6'- 2 H 5 )[biphenyl]-3-yl]methyl ⁇ -4-[(methylsulfonyl)amino]-2-azabicyclo[3.1.1]heptane-2-carboxylate.
  • Example 8G The compound synthesized in Example 8G (26.3 mg), phenyl-d5-boronic acid (10.5 mg), potassium carbonate (22.9 mg), and 1,4-dioxane (0.37 mL) were mixed at room temperature with [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (3.2 mg) and water (0.09 mL), and stirred at 60°C for 2.5 hours under a nitrogen atmosphere. The mixture was diluted with ethyl acetate, washed with water and saturated saline, and dried over sodium sulfate.
  • Example 55 N-[(3S,4R)-5-fluoro-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-(1,3-oxazol-4-ylcarbonyl)-2-azabicyclo[3.1.1]heptan-4-yl]methanesulfonamide
  • 55A N-[(3S,4R)-5-fluoro-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-(1,3-oxazol-4-ylcarbonyl)-2-azabicyclo[3.1.1]heptan-4-yl]methanesulfonamide
  • the title compound 13 mg, yield: 89%) was obtained as a single diastereomer and a single enantiomer in the same manner as in Example 5H.
  • Example 56 N- ⁇ (3S,4S)-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-propanoyl-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • 56A N- ⁇ (3S,4S)-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-propanoyl-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • the compound synthesized in Example 25B 40 mg
  • tetrahydrofuran 1.0 mL
  • Example 57 N-[(3S,4S)-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-(2-methylpropanoyl)-2-azabicyclo[3.1.1]heptan-4-yl]methanesulfonamide
  • (57A) N-[(3S,4S)-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-(2-methylpropanoyl)-2-azabicyclo[3.1.1]heptan-4-yl]methanesulfonamide
  • the title compound (16 mg, yield: 38%) was obtained as a single diastereomer and a single enantiomer in the same manner as in Example 56A.
  • Example 60 N-[3- ⁇ [2-(3-chlorophenyl)-3-fluoropyridin-4-yl]methyl ⁇ -2-(cyclopropylcarbonyl)-2-azabicyclo[3.1.1]heptan-4-yl]methanesulfonamide (60A) 2-tert-butyl 3-methyl 3-[(2-bromo-3-fluoropyridin-4-yl)methyl]-4-oxo-2-azabicyclo[3.1.1]heptane-2,3-dicarboxylate Using 2-bromo-4-(bromomethyl)-3-fluoropyridine (CAS registration number: 1227585-59-2, 1.00 g) and 2-oxo-4-azabicyclo[3.1.1]heptane-3,4-dicarboxylate O4-tert-butyl O3-methyl (CAS registration number: 2241048-56-4, 1.00 g), the title compound (1.46 g, yield: 84%) was obtained in the same manner as in Example
  • Example 62 N- ⁇ (3S,4S)-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-[(1-hydroxycyclobutyl)carbonyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • (62A) N- ⁇ (3S,4S)-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-[(1-hydroxycyclobutyl)carbonyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • the title compound (18 mg, yield: 31%) was obtained as a single diastereomer and a single enantiomer in the same manner as in Example 31C.
  • Example 63 N- ⁇ (3S,4R)-3-[(2,5-difluoro[biphenyl]-3-yl)methyl]-5-fluoro-2-[(2R)-2-hydroxypropanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide (63A) 2-tert-butyl 3-methyl 3-(3-bromo-2,5-difluorobenzyl)-5-fluoro-4-oxo-2-azabicyclo[3.1.1]heptane-2,3-dicarboxylate
  • the compound synthesized in Example 12C 500 mg
  • 1-bromo-3-(bromomethyl)-2,5-difluorobenzene CAS registration number: 1805523-99-2, 597 mg
  • N,N-dimethylformamide (8.7 mL) were mixed and added with cesium carbonate (850 mg) at 0°C, and the mixture was stirred at room temperature for
  • Example 63J N- ⁇ (3S,4R)-3-[(2,5-difluoro[biphenyl]-3-yl)methyl]-5-fluoro-2-[(2R)-2-hydroxypropanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • Example 64 N- ⁇ (3S,4S)-2-[(2R)-2-cyclopropyl-2-hydroxyacetyl]-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • 64A N- ⁇ (3S,4S)-2-[(2R)-2-cyclopropyl-2-hydroxyacetyl]-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • the title compound 22 mg, yield: 38%) was obtained as a single diastereomer and a single enantiomer in the same manner as in Example 31C.
  • Example 65 Ethyl (3S,4S)-3-[(2-fluoro[biphenyl]-3-yl)methyl]-4-[(methylsulfonyl)amino]-2-azabicyclo[3.1.1]heptane-2-carboxylate (65A) Ethyl (3S,4S)-3-[(2-fluoro[biphenyl]-3-yl)methyl]-4-[(methylsulfonyl)amino]-2-azabicyclo[3.1.1]heptane-2-carboxylate The compound synthesized in Example 25B (30 mg), N,N-diisopropylethylamine (50 mg), and tetrahydrofuran (1.0 mL) were mixed at room temperature and ethyl chloroformate (14 mg) was added and stirred for 2 hours.
  • reaction solution was poured into water and extracted with ethyl acetate.
  • Example 66 N-[(3S,4R)-5-fluoro-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2- ⁇ [(1S,2S)-2-fluorocyclopropyl]carbonyl ⁇ -2-azabicyclo[3.1.1]heptan-4-yl]methanesulfonamide (66A) tert-butyl (3S*,4R*)-5-fluoro-3-[(2-fluoro[biphenyl]-3-yl)methyl]-4-[(methylsulfonyl)amino]-2-azabicyclo[3.1.1]heptane-2-carboxylate
  • phenylboronic acid (576 mg)
  • Example 68 N- ⁇ (3S,4S)-3-[3-(5-chlorothiophen-3-yl)-2-fluorobenzyl]-2-[(2R)-2-hydroxypropanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide (68A) tert-Butyl (3S,4S)-3-[3-(5-chlorothiophen-3-yl)-2-fluorobenzyl]-4-[(methylsulfonyl)amino]-2-azabicyclo[3.1.1]heptane-2-carboxylate.
  • Example 21A The compound synthesized in Example 21A (100 mg), cesium carbonate (155 mg), 4-bromo-2-chlorothiophene (40 mg), (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate (16 mg), water (1.0 mL) and 1,4-dioxane (6.0 mL) were stirred at 80°C for 10 hours under a nitrogen atmosphere. The mixture was diluted with ethyl acetate and washed with water and saturated saline.
  • This reaction mixture was added to a mixture of the compound synthesized in Example 66C (40.0 mg), N,N-diisopropylethylamine (0.111 mL), and dichloromethane (1 mL) prepared separately at 0° C., and the mixture was stirred at room temperature for 2 hours.
  • the mixture was diluted with ethyl acetate, washed with water, hydrochloric acid (1 M), saturated sodium bicarbonate solution, and saturated saline solution, and dried over sodium sulfate.
  • Example 70 N- ⁇ (3S,4R)-5-fluoro-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-[(2R)-oxetan-2-ylcarbonyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • 70A N- ⁇ (3S,4R)-5-fluoro-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-[(2R)-oxetan-2-ylcarbonyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • the compound synthesized in Example 66C (30.0 mg), (2R)-oxetane-2-carboxylic acid (10.7 mg), 1-hydroxy-7-azabenzotriazole (9.5 mg), triethylamine (0.0388 mL), and N,N-dimethylformamide (1 mL)
  • Example 71 N- ⁇ (3S,4R)-5-fluoro-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-[(1-hydroxycyclopropyl)carbonyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • (71A) N- ⁇ (3S,4R)-5-fluoro-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-[(1-hydroxycyclopropyl)carbonyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • the compound synthesized in Example 66C (30.0 mg), 1-hydroxy-1-cyclopropanecarboxylic acid (10.7 mg), 1-hydroxy-7-azabenzotriazole (9.5 mg), triethylamine (0.0388 mL), and N,N-dimethylformamide (1 mL) were mixed at room temperature and 1-(
  • Example 72 N- ⁇ (3S,4S)-2-(3,3-difluoro-2-hydroxypropanoyl)-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • 72A N- ⁇ (3S,4S)-2-(3,3-difluoro-2-hydroxypropanoyl)-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • the title compound 40 mg was obtained in the same manner as in Example 5H.
  • Example 72B N- ⁇ (3S,4S)-2-(3,3-difluoro-2-hydroxypropanoyl)-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • CHIRALCEL registered trademark
  • Example 74 N-[(3S,4R)-3-[(2,5-difluoro[biphenyl]-3-yl)methyl]-5-fluoro-2-(2-hydroxy-2-methylpropanoyl)-2-azabicyclo[3.1.1]heptan-4-yl]methanesulfonamide (74A) tert-Butyl (3S,4R)-3-(3-bromo-2,5-difluorobenzyl)-5-fluoro-4-[(methylsulfonyl)amino]-2-azabicyclo[3.1.1]heptane-2-carboxylate
  • Example 75 N- ⁇ (3S,4S)-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-[(2S)-3-fluoro-2-hydroxypropanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • 75A N- ⁇ (3S,4S)-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-[(2S)-3-fluoro-2-hydroxypropanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • the title compound (12.2 mg, yield: 60%) was obtained as a single diastereomer and a single enantiomer in the same manner as in Example 5H.
  • Example 76 N- ⁇ (3S,4S)-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-[(2R)-2-hydroxy( 2H4 )propanoyl]-2-azabicyclo[ 3.1.1 ]heptan-4-yl ⁇ methanesulfonamide
  • 76A N-[(3S,4S)-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-(2-oxopropanoyl)-2-azabicyclo[3.1.1]heptan-4-yl]methanesulfonamide
  • the compound synthesized in Example 25B (107 mg), pyruvic acid (0.0234 mL) and N,N-dimethylformamide (2.6 mL) were mixed at room temperature with N,N-diisopropylethylamine (0.134 mL) and O-(7-azabenzotriazol-1-yl)-N,N,
  • Example 77 N-[(3S,4R)-3-[(3'-chloro-2,5-difluoro[biphenyl]-3-yl)methyl]-5-fluoro-2-(2-hydroxy-2-methylpropanoyl)-2-azabicyclo[3.1.1]heptan-4-yl]methanesulfonamide (77A) tert-Butyl (3S,4R)-3-[(3'-chloro-2,5-difluoro[biphenyl]-3-yl)methyl]-5-fluoro-4-[(methylsulfonyl)amino]-2-azabicyclo[3.1.1]heptane-2-carboxylate
  • the compound synthesized in Example 74A (192 mg), 3-chlorophenylboronic acid (88 mg), potassium carbonate (155 mg), tetrakis(triphenylphosphine)palladium(0) (33 mg), 1,4-dioxane (6.2
  • Example 77B N- ⁇ (3S,4R)-3-[(3'-chloro-2,5-difluoro[biphenyl]-3-yl)methyl]-5-fluoro-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide hydrochloride Using the compound synthesized in Example 77A (124 mg), the crude title compound (110 mg) was obtained as a single diastereomer and a single enantiomer in the same manner as in Example 8H.
  • Example 78 N- ⁇ (3S,4R)-2- ⁇ [(1S)-2,2-difluorocyclopropyl]carbonyl ⁇ -5-fluoro-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • (78A) N- ⁇ (3S,4R)-2- ⁇ [(1S)-2,2-difluorocyclopropyl]carbonyl ⁇ -5-fluoro-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • the compound synthesized in Example 66C (30.0 mg), (1S)-2,2-difluorocyclopropane-1-carboxylic acid (12.8 mg), 1-hydroxy-7-azabenzotriazole (9.5 mg), triethylamine (0.0388
  • This reaction mixture and N,N-diisopropylethylamine (0.33 mL) were added to a mixture of the compound synthesized in Example 74C (50 mg) and dichloromethane (3.0 mL) prepared separately at room temperature over 30 minutes, and the mixture was stirred for 15 minutes. 10% aqueous ammonia (3.0 mL) was added, and the mixture was stirred for 5 minutes, after which an aqueous ammonium chloride solution was added. The mixture was extracted with ethyl acetate, washed with saturated saline, and dried over sodium sulfate.
  • Example 80 N- ⁇ (3S,4S)-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-[(2R)-2-hydroxypropanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ ethanesulfonamide (80A) tert-Butyl (3S,4S)-3-(3-bromo-2-fluorobenzyl)-4-[(ethylsulfonyl)amino]-2-azabicyclo[3.1.1]heptane-2-carboxylate.
  • Ethanesulfonyl chloride (204 mg) was added to a mixture of the compound synthesized in Example 8F (300 mg), triethylamine (0.105 mL), and tetrahydrofuran (3.0 mL), and the mixture was stirred at room temperature for 12 hours. The mixture was diluted with ethyl acetate, washed with water and saturated saline, and dried over sodium sulfate.
  • the mixture was diluted with ethyl acetate, washed with water and saturated saline, and dried over sodium sulfate. After filtration, the solvent was distilled off under reduced pressure to obtain 130 mg of the crude title compound as a single diastereomer and a single enantiomer.
  • Example 81 N- ⁇ 3-[(2,5-difluoro[biphenyl]-3-yl)methyl]-2-[(2R)-2-hydroxypropanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ ethanesulfonamide (81A) tert-Butyl 3-(3-bromo-2,5-difluorobenzyl)-4-[(ethylsulfonyl)amino]-2-azabicyclo[3.1.1]heptane-2-carboxylate.
  • Ethanesulfonyl chloride (277 mg) was added to a mixture of the compound synthesized in Example 58E (600 mg), triethylamine (437 mg) and tetrahydrofuran (4.0 mL), and the mixture was stirred at room temperature for 1 hour. The mixture was diluted with ethyl acetate, washed with water and saturated saline, and dried over sodium sulfate.
  • Example 81F N- ⁇ 3-[(2,5-difluoro[biphenyl]-3-yl)methyl]-2-[(2R)-2-hydroxypropanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ ethanesulfonamide
  • Example 83 N- ⁇ (3S,4R)-5-fluoro-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-[(2R)-2-hydroxypropanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ ethanesulfonamide (83A) tert-Butyl (3S*,4R*)-4-amino-5-fluoro-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-azabicyclo[3.1.1]heptane-2-carboxylate
  • the compound synthesized in Example 23D (15.0 mg), phenylboronic acid (8.8 mg), (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl) [2-(2'-amino-1,1'-biphenyl)] palladium (II) methanesulfon
  • Example 84 N-[(3S,4R)-5-fluoro-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-(1,2-oxazol-3-ylcarbonyl)-2-azabicyclo[3.1.1]heptan-4-yl]methanesulfonamide
  • (84A) N-[(3S,4R)-5-fluoro-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-(1,2-oxazol-3-ylcarbonyl)-2-azabicyclo[3.1.1]heptan-4-yl]methanesulfonamide
  • the compound synthesized in Example 66C (20.0 mg), isoxazole-3-carboxylic acid (7.9 mg), 1-hydroxy-7-azabenzotriazole (6.4 mg), triethylamine (0.0259 mL), and N,N-dimethylformamide (1 mL) were mixed at room temperature and 1-(3
  • Example 85 N-[(3S,4R)-5-fluoro-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-(2-fluoro-2-methylpropanoyl)-2-azabicyclo[3.1.1]heptan-4-yl]methanesulfonamide (85A) N-[(3S,4R)-5-fluoro-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-(2-fluoro-2-methylpropanoyl)-2-azabicyclo[3.1.1]heptan-4-yl]methanesulfonamide Using the compound synthesized in Example 66C (20.0 mg) and 2-fluoroisobutyric acid (7.4 mg), the title compound was obtained in a similar manner to Example 84A, giving 18.6 mg (yield: 83%) as a single diastereomer and a single enantiomer.
  • Example 86 N- ⁇ (3S,4S)-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-[(3S)-3-hydroxybutanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • (86A) N- ⁇ (3S,4S)-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-[(3S)-3-hydroxybutanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • 72 mg (yield: 65%) of the title compound was obtained as a single diastereomer and a single enantiomer in the same manner as in Example 31C.
  • Example 87 N- ⁇ (3S,4R)-3-[(2,5-difluoro[biphenyl]-3-yl)methyl]-5-fluoro-2-[(2R)-2-hydroxy( 2H4 )propanoyl]-2-azabicyclo[ 3.1.1 ]heptan-4-yl ⁇ methanesulfonamide
  • (87A) N-[(3S,4R)-3-[(2,5-difluoro[biphenyl]-3-yl)methyl]-5-fluoro-2-(2-oxopropanoyl)-2-azabicyclo[3.1.1]heptan-4-yl]methanesulfonamide.
  • Example 74C The compound synthesized in Example 74C (45.0 mg), pyruvic acid (0.0216 mL) and N,N-dimethylformamide (1.01 mL) were mixed at room temperature with N,N-diisopropylethylamine (0.0696 mL) and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (115 mg) and stirred for 1 hour. Diluted with ethyl acetate, washed with water and saturated saline, and dried over sodium sulfate.
  • Example 88 N- ⁇ (3S,4S)-3-[(2,5-difluoro[biphenyl]-3-yl)methyl]-2-[(2R)-2-hydroxy( 2H4 )propanoyl]-2-azabicyclo[ 3.1.1 ]heptan-4-yl ⁇ methanesulfonamide (88A) 2,5-Difluoro-3-methyl[biphenyl] 3-Bromo-2,5-difluorotoluene (CAS registration number: 1416354-32-9, 550 mg), phenylboronic acid (648 mg), tripotassium phosphate (1.69 g), and tetrahydrofuran (26.6 mL) were mixed at room temperature with (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl) [2-(2'-amino-1,1'-biphenyl)] palladium
  • Molybdenum oxide (VI) (1.45 g) was added at 0° C., sodium borohydride (1.53 g) was added in small portions, and the mixture was stirred at 0° C. for 1 hour. Saturated sodium bicarbonate water was added to the reaction mixture.
  • a mixture of the compound synthesized in Example 88E (11.3 g) and methanol (260 mL) was prepared, and molybdenum oxide (VI) (22.8 g) was added at 0° C., sodium borohydride (23.9 g) was added in small portions, and the mixture was stirred at 0° C. for 1 hour. Saturated sodium bicarbonate water was added to the reaction mixture.
  • Example 66C The compound synthesized in Example 66C (40.9 mg), pyruvic acid (0.0100 mL), triethylamine (0.0397 mL), and N,N-dimethylformamide (3 mL) were mixed at room temperature and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (54.4 mg) was added and stirred for 3 hours. The mixture was diluted with ethyl acetate, washed with water and saturated saline, and dried over sodium sulfate.
  • Example 90 N- ⁇ (3S,4R)-5-fluoro-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-[(2R)-2-hydroxy( 2H4 )propanoyl]-2-azabicyclo[ 3.1.1 ]heptan-4-yl ⁇ ethanesulfonamide (90A) N-[(3S,4R)-5-fluoro-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-(2-oxopropanoyl)-2-azabicyclo[3.1.1]heptan-4-yl]ethanesulfonamide
  • the compound synthesized in Example 83E (43.8 mg), pyruvic acid (0.0105 mL), triethylamine (0.0411 mL), and N,N-dimethylformamide (3 mL) were mixed at room temperature and O-(7-azabenzotriazol-1-yl)-N,N,N'
  • Example 91 N- ⁇ 3-[(2,5-difluoro[biphenyl]-3-yl)methyl]-5-fluoro-2-[(2R)-2-hydroxypropanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ ethanesulfonamide (91A) tert-Butyl 4-amino-3-(3-bromo-2,5-difluorobenzyl)-5-fluoro-2-azabicyclo[3.1.1]heptane-2-carboxylate To a mixture of the compound synthesized in Example 63C (2.57 g), methanol (95 mL) and molybdenum (VI) oxide (2.47 g), lithium borohydride (about 2 M tetrahydrofuran solution) (34.3 mL) was slowly added dropwise over 30 minutes at room temperature and stirred for 30 minutes.
  • methanol 95 mL
  • molybdenum oxide 34.3 mL
  • Example 58E To a mixture of the compound synthesized in Example 58E (400 mg) and tetrahydrofuran (10 mL), N,N-diisopropylethylamine (0.492 mL) and ethanesulfonyl chloride (0.181 mL) were added and stirred at room temperature for 3 hours. N,N-diisopropylethylamine (0.985 mL) and ethanesulfonyl chloride (0.363 mL) were added and stirred at room temperature for 1 hour. Water was added to the reaction mixture, and it was extracted with ethyl acetate. The organic layer was washed with saturated saline and dried over anhydrous sodium sulfate.
  • Example 93 N- ⁇ (3S,4S)-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-[2-(1H-pyrazol-1-yl)propanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • (93A) N- ⁇ (3S,4S)-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-[2-(1H-pyrazol-1-yl)propanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • the title compound was obtained in a similar manner to Example 31C to obtain 9.7 mg (yield: 16%).
  • Example 94 N- ⁇ (3S,4S)-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-[(2R)-2-hydroxy( 2H4 )propanoyl]-2-azabicyclo[ 3.1.1 ]heptan-4-yl ⁇ ethanesulfonamide
  • (94A) N-[(3S,4S)-3-[(2-fluoro[biphenyl]-3-yl)methyl]-2-(2-oxopropanoyl)-2-azabicyclo[3.1.1]heptan-4-yl]ethanesulfonamide
  • the compound synthesized in Example 80C (60.0 mg), pyruvic acid (0.0147 mL), triethylamine (0.0587 mL), and N,N-dimethylformamide (2 mL) were mixed at room temperature and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethylur
  • Example 95 N- ⁇ 3-[(2,5-difluoro[biphenyl]-3-yl)methyl]-5-fluoro-2-[2-hydroxy( 2H4 )propanoyl]-2-azabicyclo[ 3.1.1 ]heptan-4-yl ⁇ ethanesulfonamide
  • (95A) N- ⁇ 3-[(2,5-difluoro[biphenyl]-3-yl)methyl]-5-fluoro-2-(2-oxopropanoyl)-2-azabicyclo[3.1.1]heptan-4-yl ⁇ ethanesulfonamide
  • the compound synthesized in Example 91E (88.8 mg), pyruvic acid (0.0412 mL) and N,N-dimethylformamide (1.93 mL) were mixed at room temperature with N,N-diisopropylethylamine (0.133 mL) and O-(7-azabenzotriazol-1-yl)-N
  • Example 96 N- ⁇ 3-[(2,5-difluoro[biphenyl]-3-yl)methyl]-5-fluoro-2-[(2R)-2-hydroxypropanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ ethenesulfonamide
  • (96A) N- ⁇ 3-[(2,5-difluoro[biphenyl]-3-yl)methyl]-5-fluoro-2-azabicyclo[3.1.1]heptan-4-yl ⁇ ethenesulfonamide hydrochloride Using the compound (16.9 mg) synthesized in Example 91C, 14.9 mg of the crude title compound was obtained as a single diastereomer (racemate) in the same manner as in Example 8H.
  • Example 76A Sodium borohydride (12.1 mg) was added to a mixture of the compound (64.0 mg) synthesized in Example 76A and tetrahydrofuran (2.1 mL) at room temperature, and the mixture was stirred at room temperature for 1 hour. The mixture was diluted with ethyl acetate, and an aqueous solution of ammonium chloride was added. The organic layer was washed with saturated saline and then dried over sodium sulfate.
  • Example 100 N- ⁇ (3S,4R)-3-[(2,5-difluoro[biphenyl]-3-yl)methyl]-5-fluoro-2-[(2R)-2-hydroxy(2- 2 H)propanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide (100A) N- ⁇ (3S,4R)-3-[(2,5-difluoro[biphenyl]-3-yl)methyl]-5-fluoro-2-[2-hydroxy(2- 2 H)propanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide.
  • Example 100B N- ⁇ (3S,4R)-3-[(2,5-difluoro[biphenyl]-3-yl)methyl]-5-fluoro-2-[(2R)-2-hydroxy(2- 2 H)propanoyl]-2-azabicyclo[3.1.1]heptan-4-yl ⁇ methanesulfonamide
  • CHIRALPAK registered trademark
  • the reference compound or test compound was dissolved in DMSO (final concentration of DMSO was 0.5%) and diluted with assay buffer (20 mM HEPES, Hank's balanced salt solution, 0.1% BSA). After the addition of the test compound or reference compound, the difference between the maximum and minimum fluorescence values from 5 to 7 seconds was used as an index. The value of the wells to which an assay buffer not containing the test compound was added was set as 0%, and the value of the wells to which 5 ⁇ M of the reference compound was added was set as 100%. The 50% effective concentration (EC50 value) was calculated from the values obtained when various concentrations of the test compound were added. Table 1 shows the EC50 value as the agonist activity of each compound.
  • Test Example 2 Increased spontaneous locomotor activity
  • Increased spontaneous locomotor activity in rodents can be an indicator of waking action.
  • mice Male C57BL/6J mice (6 weeks old, Jackson Laboratory Japan, 6-8 mice per group) were used in the experiment. The mice were acclimated for at least 1 hour in a breeding cage in a room where measurements were performed before the experiment. After acclimation, the mice were placed in a spontaneous locomotor activity measuring device equipped with an infrared sensor (behavioral analysis device SCANET-40 series, Melquest Co., Ltd.) and measurements were started.
  • SCANET-40 series an infrared sensor
  • the test compounds were suspended in 0.5 w/v% methylcellulose 400 solution (Wako Pure Chemical Industries, Ltd., Japan). Spontaneous locomotor activity was counted every 5 minutes, and the cumulative counts for 1 hour after administration were calculated for each treatment group.
  • the spontaneous motor activity of the test compound-administered group was calculated as a percentage of the spontaneous motor activity of the vehicle-administered group, which was set at 100%. The percentages are shown in Table 2.
  • Test compounds final concentration 500 ⁇ M, dissolved in DMSO/ace
  • glucose-6-phosphate final concentration 10 mM
  • glucose-6-phosphate dehydrogenase final concentration 1 U/mL
  • magnesium chloride final concentration 3.3 mM
  • a certain amount was taken, and then a 4.5-fold amount of an internal standard substance (final concentrations: phenacetin: 1 ng/mL, niflumic acid: 15 ng/mL, furosumide: 20 ng/mL)-containing acetonitrile/methanol mixture (75/25, v/v) was added to stop the reaction (0 min sample).
  • ⁇ -nicotinamide adenine dinucleotide phosphate (final concentration 1 mM) was added and incubated at 37°C for 30 min, after which a certain amount was taken and 4.5 volumes of an acetonitrile/methanol mixture (75/25, v/v) containing an internal standard was added to stop the reaction (30 min sample). After centrifugation (approximately 1200 ⁇ g, 4°C, 15 min) for both samples, a portion of the supernatant was injected into a liquid chromatograph-tandem quadrupole mass spectrometer (LC-MS/MS) for analysis.
  • LC-MS/MS liquid chromatograph-tandem quadrupole mass spectrometer
  • the metabolic stability was evaluated by comparing the test compound/internal standard ratio of the 30 min sample with that of the 0 min sample and calculating the residual rate of the test compound.
  • Table 4 summarizes the physicochemical data of the compounds described in the examples.
  • Table 5 below shows the structural formulas of the compounds obtained in each example.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PCT/JP2023/044987 2022-12-16 2023-12-15 2-アザビシクロ[3.1.1]ヘプタン化合物 Ceased WO2024128305A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2023395547A AU2023395547A1 (en) 2022-12-16 2023-12-15 2-azabicyclo[3.1.1]heptane compound
JP2024564440A JPWO2024128305A1 (cg-RX-API-DMAC7.html) 2022-12-16 2023-12-15
KR1020257019334A KR20250112793A (ko) 2022-12-16 2023-12-15 2-아자비시클로[3.1.1]헵탄 화합물
EP23903586.8A EP4635944A1 (en) 2022-12-16 2023-12-15 2-azabicyclo[3.1.1]heptane compound
CN202380092851.0A CN120603816A (zh) 2022-12-16 2023-12-15 2-氮杂双环[3.1.1]庚烷化合物
MX2025006722A MX2025006722A (es) 2022-12-16 2025-06-09 Compuesto de 2-azabiciclo[3.1.1]heptano

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022-201488 2022-12-16
JP2022201488 2022-12-16

Publications (1)

Publication Number Publication Date
WO2024128305A1 true WO2024128305A1 (ja) 2024-06-20

Family

ID=91485946

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2023/044987 Ceased WO2024128305A1 (ja) 2022-12-16 2023-12-15 2-アザビシクロ[3.1.1]ヘプタン化合物

Country Status (8)

Country Link
EP (1) EP4635944A1 (cg-RX-API-DMAC7.html)
JP (1) JPWO2024128305A1 (cg-RX-API-DMAC7.html)
KR (1) KR20250112793A (cg-RX-API-DMAC7.html)
CN (1) CN120603816A (cg-RX-API-DMAC7.html)
AU (1) AU2023395547A1 (cg-RX-API-DMAC7.html)
MX (1) MX2025006722A (cg-RX-API-DMAC7.html)
TW (1) TW202430169A (cg-RX-API-DMAC7.html)
WO (1) WO2024128305A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026019302A1 (ko) * 2024-07-18 2026-01-22 (주)셀트리온 신규한 오렉신 2 수용체 작용제 및 이의 용도

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015088000A1 (ja) 2013-12-12 2015-06-18 国立大学法人筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
WO2017135306A1 (en) 2016-02-04 2017-08-10 Takeda Pharmaceutical Company Limited Substituted piperidine compound and use thereof
WO2019027058A1 (en) 2017-08-03 2019-02-07 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND AND USE THEREOF
WO2019081939A1 (en) * 2017-10-25 2019-05-02 Chronos Therapeutics Limited 2-AZABICYCLO [3.1.1] DERIVATIVES AS ANTAGONISTS OF OREXIN-1 AND OREXIN-2 RECEPTORS
WO2020158958A1 (en) 2019-01-31 2020-08-06 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2020167701A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Pyrrolidine orexin receptor agonists
JP2020531556A (ja) * 2017-09-01 2020-11-05 クロノス セラピューティクス リミテッドChronos Therapeutics Limited オレキシン受容体拮抗薬としての置換2−アザビシクロ[3.1.1]ヘプタンおよび2−アザビシクロ[3.2.1]オクタン誘導体
WO2021108628A1 (en) 2019-11-25 2021-06-03 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
WO2021107023A1 (ja) 2019-11-27 2021-06-03 大日本住友製薬株式会社 シクロアルキルウレア誘導体
WO2022014680A1 (ja) 2020-07-17 2022-01-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 置換ピペリジン化合物及びその用途
WO2022051596A1 (en) 2020-09-03 2022-03-10 Orexia Therapeutics Limited Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
CN116969888A (zh) * 2022-04-24 2023-10-31 优领医药科技(上海)有限公司 含环丙基并环类衍生物、其药学上可接受的盐及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015056100A2 (en) 2013-10-14 2015-04-23 Marvell World Trade Ltd. Systems and methods for graphics process units power management
JP6359924B2 (ja) 2014-09-17 2018-07-18 トヨタ自動車株式会社 非接触送受電システム

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015088000A1 (ja) 2013-12-12 2015-06-18 国立大学法人筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
WO2017135306A1 (en) 2016-02-04 2017-08-10 Takeda Pharmaceutical Company Limited Substituted piperidine compound and use thereof
WO2019027058A1 (en) 2017-08-03 2019-02-07 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND AND USE THEREOF
JP2019527688A (ja) * 2017-08-03 2019-10-03 武田薬品工業株式会社 複素環化合物およびその用途
JP2020531556A (ja) * 2017-09-01 2020-11-05 クロノス セラピューティクス リミテッドChronos Therapeutics Limited オレキシン受容体拮抗薬としての置換2−アザビシクロ[3.1.1]ヘプタンおよび2−アザビシクロ[3.2.1]オクタン誘導体
WO2019081939A1 (en) * 2017-10-25 2019-05-02 Chronos Therapeutics Limited 2-AZABICYCLO [3.1.1] DERIVATIVES AS ANTAGONISTS OF OREXIN-1 AND OREXIN-2 RECEPTORS
JP2022519331A (ja) * 2019-01-31 2022-03-22 武田薬品工業株式会社 複素環化合物およびその用途
WO2020158958A1 (en) 2019-01-31 2020-08-06 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2020167701A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Pyrrolidine orexin receptor agonists
WO2021108628A1 (en) 2019-11-25 2021-06-03 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
WO2021107023A1 (ja) 2019-11-27 2021-06-03 大日本住友製薬株式会社 シクロアルキルウレア誘導体
WO2022014680A1 (ja) 2020-07-17 2022-01-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 置換ピペリジン化合物及びその用途
WO2022051596A1 (en) 2020-09-03 2022-03-10 Orexia Therapeutics Limited Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
CN116969888A (zh) * 2022-04-24 2023-10-31 优领医药科技(上海)有限公司 含环丙基并环类衍生物、其药学上可接受的盐及其制备方法和应用

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
"Comprehensive Organic Transformations", 1989, ACADEMIC PRESS, INC.
CELL, vol. 92, 1998, pages 573 - 585
CELL, vol. 98, 1999, pages 365 - 376
CHEM. RES. TOXICOL, vol. 17, 2004, pages 3 - 16
CNS DRUGS, vol. 27, 2013, pages 83 - 90
CURR. OPIN. DRUG DISCOVERY DEV, vol. 4, 2001, pages 55 - 59
LANCET, vol. 355, 2000, pages 39 - 40
NEURON, vol. 38, 2003, pages 715 - 730
no. 1416354-32-9
NOBUO IZUMIYAMARUZEN ET AL., FUNDAMENTALS AND EXPERIMENTS OF PEPTIDE SYNTHESIS, 1985
PROC. NATL. ACAD. SCI. USA, vol. 101, 2004, pages 4649 - 4654
PROG. MED., vol. 5, 1985, pages 2157 - 2161
See also references of EP4635944A1
SHOICHI KUSUMOTOMARUZEN ET AL.: "The Experimental Science", 1990, THE CHEMICAL SOCIETY OF JAPAN
T. W. GREENEP. G. WUTS: "Greene's Protective Groups in Organic Synthesis", 2006, JOHN WILEY & SONS, INC.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026019302A1 (ko) * 2024-07-18 2026-01-22 (주)셀트리온 신규한 오렉신 2 수용체 작용제 및 이의 용도

Also Published As

Publication number Publication date
CN120603816A (zh) 2025-09-05
JPWO2024128305A1 (cg-RX-API-DMAC7.html) 2024-06-20
EP4635944A1 (en) 2025-10-22
AU2023395547A1 (en) 2025-06-26
KR20250112793A (ko) 2025-07-24
TW202430169A (zh) 2024-08-01
MX2025006722A (es) 2025-07-01

Similar Documents

Publication Publication Date Title
US8153658B2 (en) Piperidine derivative or salt thereof
CN108026056B (zh) 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑酰胺衍生物化合物及其药物组合物
AU2014369180B2 (en) Heteroaryl butanoic acid derivatives as LTA4H inhibitors
EP3199533B1 (en) Pyrazole compound and pharmaceutical use thereof
TW201427953A (zh) 可作爲激酶調節劑之經雜芳基取代的吡啶化合物
KR20020082896A (ko) 프로테아제 억제제
AU2014369180A1 (en) Heteroaryl butanoic acid derivatives as LTA4H inhibitors
RU2396257C2 (ru) Производные 4-аминопиперидина
TWI851890B (zh) 抗病毒性1,3-二氧代茚化合物
US20250221966A1 (en) Rxfp1 agonists
KR20250112793A (ko) 2-아자비시클로[3.1.1]헵탄 화합물
CN101300226B (zh) 对组蛋白脱乙酰酶具有抑制活性的烷基氨甲酰基萘氧基辛烯酰基羟基酰胺衍生物及其制备方法
JPWO2005068427A1 (ja) カルボキサミド誘導体およびその用途
KR101950057B1 (ko) 파록세틴 유도체
JP2004526662A (ja) プロテアーゼ阻害剤
CN101522610A (zh) 氨基醇的硝酸酯
JP2009502739A (ja) タキキニン受容体拮抗剤としてのピペリジン誘導体
US20050038072A1 (en) Nitrogeneous cyclic ketone derivative, process for producing the same, and use
JP2005513083A (ja) プロテアーゼ阻害剤
TWI670262B (zh) 新穎雜芳基丁酸衍生物
US20040192674A1 (en) Cathepsin L inhibitors
HK1258700A1 (zh) 锥虫抑制剂
EA045146B1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
TW201341380A (zh) 磺醯胺衍生物及其用途
US20060025412A1 (en) Peptide deformylase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23903586

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: AU2023395547

Country of ref document: AU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025010662

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2024564440

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2023395547

Country of ref document: AU

Date of ref document: 20231215

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2023903586

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023903586

Country of ref document: EP

Effective date: 20250716

WWP Wipo information: published in national office

Ref document number: 1020257019334

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 202380092851.0

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 202380092851.0

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2023903586

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 112025010662

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20250527